U.S. patent application number 12/314195 was filed with the patent office on 2009-10-15 for chimeric immunoreceptor useful in treating human cancers.
This patent application is currently assigned to City of Hope. Invention is credited to Michael Jensen.
Application Number | 20090257994 12/314195 |
Document ID | / |
Family ID | 42233623 |
Filed Date | 2009-10-15 |
United States Patent
Application |
20090257994 |
Kind Code |
A1 |
Jensen; Michael |
October 15, 2009 |
Chimeric immunoreceptor useful in treating human cancers
Abstract
The present invention relates to chimeric transmembrane
immunoreceptors, named "zetakines," comprised of an extracellular
domain comprising a soluble receptor ligand linked to a support
region capable of tethering the extracellular domain to a cell
surface, a transmembrane region and an intracellular signalling
domain. Zetakines, when expressed on the surface of T lymphocytes,
direct T cell activity to those specific cells expressing a
receptor for which the soluble receptor ligand is specific.
Zetakine chimeric immunoreceptors represent a novel extension of
antibody-based immunoreceptors for redirecting the antigen
specificity of T cells, with application to treatment of a variety
of cancers, particularly via the autocrin/paracrine cytokine
systems utilized by human malignancy. In a preferred embodiment is
a glioma-specific immunoreceptor comprising the extracellular
targetting domain of the IL-13R.alpha.2-specific IL-13 mutant
IL-13(E13Y) linked to the Fc region of IgG, the transmembrane
domain of human CD4, and the human CD3 zeta chain.
Inventors: |
Jensen; Michael; (Sierra
Madre, CA) |
Correspondence
Address: |
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
1425 K STREET, N.W., SUITE 800
WASHINGTON
DC
20005
US
|
Assignee: |
City of Hope
Duarte
CA
|
Family ID: |
42233623 |
Appl. No.: |
12/314195 |
Filed: |
December 5, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11274344 |
Nov 16, 2005 |
7514537 |
|
|
12314195 |
|
|
|
|
10134645 |
Apr 30, 2002 |
|
|
|
11274344 |
|
|
|
|
60286981 |
Apr 30, 2001 |
|
|
|
Current U.S.
Class: |
424/93.71 ;
435/320.1; 530/350 |
Current CPC
Class: |
A61K 38/1774 20130101;
C07K 19/00 20130101; C07H 21/04 20130101; C07K 14/70514 20130101;
A61P 35/00 20180101; C12N 15/63 20130101; C12N 5/0636 20130101;
A61K 38/2086 20130101; A61K 35/17 20130101; C07K 14/5437 20130101;
C07K 2319/30 20130101; C07K 2319/00 20130101; C07K 14/7051
20130101; C07K 14/7155 20130101; C07K 16/46 20130101 |
Class at
Publication: |
424/93.71 ;
530/350; 435/320.1 |
International
Class: |
A61K 45/00 20060101
A61K045/00; C07K 14/00 20060101 C07K014/00; C12N 15/74 20060101
C12N015/74; A61P 35/00 20060101 A61P035/00 |
Goverment Interests
[0002] This invention was made with government support in the form
of Cancer Center Support Grant no. P30-CA33572-21 from the United
States Department of Health and Human Services, National Institutes
of Health. The United States government has certain rights in the
invention.
Claims
1. A chimeric immunoreceptor comprising SEQ ID NO:22.
2. A chimeric immunoreceptor encoded by a nucleic acid sequence
comprising SEQ ID NO:19 or SEQ ID NO:23.
3. A method for treating human cancer, comprising administering to
a human suffering from a glioma that overexpresses IL13.alpha.2
receptor a plurality of T lymphocyte cells expressing an
immunoreceptor of claim 1 or claim 2.
4. A vector which comprises a nucleic acid comprising SEQ ID NO: 19
or SEQ ID NO:23.
5. The vector which consists essentially of SEQ ID NO:19.
6. The vector which consists essentially of SEQ ID NO:23.
Description
[0001] This application is a continuation-in-part of prior
co-pending application U.S. Ser. No. 11/274,344, filed Nov. 16,
2005, which is a continuation-in-part of application U.S. Ser. No.
10/134,645, filed Apr. 30, 2002, now abandoned, which claims the
benefit of application U.S. 60/286,981, filed Apr. 30, 2001. This
application also claims the benefit of application U.S. 61/091,915,
filed Aug. 26, 2008. The disclosures of all of the above
applications are hereby incorporated by reference in their
entirety.
TECHNICAL FIELD
[0003] The invention relates to the field of biomedicine and
specifically methods useful for cancer therapy. In particular,
embodiments of the invention relate to methods for specific CTL
immunotherapeutic strategies for cancer including the use of
genetically-modified T lymphocytes expressing chimeric
immunoreceptors in the treatment of human brain tumors and other
cancers.
BACKGROUND OF THE INVENTION
[0004] Primary brain tumors are the third leading contributor to
cancer-related mortality in young adults, are the second leading
contributor in children, and appear to be increasing in incidence
both in the pediatric and geriatric population.sup.1-4. Gliomas are
the most common type of primary brain tumors; 20,000 cases are
diagnosed and 14,000 glioma-related deaths occur annually in the
United States.sup.5-8. Gliomas are heterogeneous with respect to
their malignant behavior and, in their most common and aggressive
forms, anaplastic astrocytoma (AA-grade III) and glioblastoma
multiforme (GBM-grade IV), are rapidly progressive and nearly
uniformly lethal.sup.9; 10. Currently available therapeutic
modalities have minimal curative potential for these high-grade
tumors and often exacerbate the already severe morbidities imposed
by their location in the central nervous system. Thus patients with
malignant glioma are often struck in the most productive period of
their lives; frequent deterioration of mental faculties and a high
case:fatality ratio contribute to the unique personal and social
impact of these tumors.
[0005] The cornerstones of oncologic management of malignant glioma
are resection and radiation therapy.sup.11-16. With modern surgical
and radiotherapeutic techniques the mean duration of survival has
increased to 82 weeks for glioblastoma multiforme and 275 weeks for
anaplastic astrocytoma, although 5-year survival rates have only
increased from 3 to 6% for glioblastoma multiforme and 12.1% for
anaplastic astrocytoma.sup.6-8. The major prognostic indicators for
prolonged survival are younger age (<40 yrs) and performance
status (KPS score >70).sup.17. Resections of >90% of bulky
tumors are usually attempted provided that vital functional anatomy
is spared. When used in conjunction with post-operative radiation
therapy, the impact of extent of resection on duration of survival
is less clear.sup.18; 19. The addition of chemotherapy to resection
and radiation provides only marginal survival advantage to patients
with anaplastic astrocytoma or glioblastoma multiforme.sup.20-23.
Nitrosureas alone or in combination with procarbazine and
vincristine are the conventional drugs used in the community and
appear to improve the 1-year and 2-year survival rates by 15%
without impacting on the overall median survival.sup.24; 25. More
aggressive regimens incorporating platinum-based drugs and
topoisomerase inhibitors are under investigation.sup.26. The role
of high-dose chemotherapy with stem cell rescue has not been
substantiated to date.sup.27-29.
[0006] Approximately 80% of recurrent tumors arise from
radiographically enhancing remnants of the original incompletely
resected tumor.sup.10; 30; 31. Provided recurrences are unifocal
and amenable in their location to aggressive re-resection, this
approach can extend survival duration, particularly for patients
with anaplastic astrocytoma and those glioblastoma multiforme
patients with a KPS>70..sup.10 The median survival of recurrent
glioblastoma multiforme patients treated with re-resection is 36
weeks.sup.10; 30; 31. Radiation therapy in the form of either
brachytherapy or stereotactic radiosurgery may extend the duration
of survival in re-resected recurrent glioblastoma multiforme
patients by only 10-12 weeks.sup.32. The use of chemotherapy in the
setting of recurrent disease should be in the context of available
clinical trials, as its efficacy in this patient population is
unsubstantiated.
[0007] The continued dismal prognosis of malignant glioma has
prompted the clinical investigation of novel therapeutic entities,
including, but not limited to: gene therapy (TK-suicide, antisense
inhibition of tumor growth factor receptors, conditionally lethal
viral vectors), immunotherapy (antibody, tumor cell vaccines,
immunotoxins, adoptive transfer of activated lymphocytes), and
anti-angiogenesis approaches.sup.33-40. The multiplicity of
challenges faced in the development of effective adjuvant therapies
for malignant glioma include the extensive infiltrative growth of
tumor cells into normal brain parenchyma, the capacity of soluble
factors elaborated from these tumors to attenuate the development
of immune responses, and the difficulty of establishing clinically
meaningful therapeutic ratios when administering therapeutics into
the central nervous system (CNS). Early clinical evaluation of
novel therapeutics is clearly indicated in this patient
population.
[0008] Recently, receptors for transferrin and growth factors have
been the subject of experimental glioma therapeutics utilizing
ligands for these receptors conjugated to toxins or
radionucleotides as a delivery system.sup.41. The specificity of
this approach relies on the unique expression or over-expression of
targeted receptors on glioma cells compared to normal brain.
Interestingly, some receptor complexes for interleukins utilized by
the immune system are expressed by gliomas, in particular
high-affinity IL-13 receptors.sup.42-48. Unlike the IL-13 receptor
trimolecular complex utilized by the immune system, which consists
of the IL-13R.alpha.1, the IL-4R.beta., and .gamma.c, glioma cells
overexpress a unique IL-13R.alpha.2 chain capable of binding IL-13
independently of the requirement for IL-4R.beta. or
.gamma.c.sup.44; 49; 50. Like its homologue IL-4, IL-13 has
pleotrophic immunoregulatory activity outside the CNS.sup.51-53.
Both cytokines stimulate IgE production by B lymphocytes and
suppress pro-inflammatory cytokine production by macrophages. The
immunobiology of IL-13 within the CNS is largely unknown.
[0009] Detailed studies by Debinski et al. using autoradiography
with radiolabeled IL-13 have demonstrated abundant IL-13 binding on
nearly all malignant glioma tissues studied.sup.42; 45; 46; 48.
Moreover, the binding is highly homogeneous within tumor sections
and from single cell analysis.sup.46; 48. Scatchard analyses of
IL-13 binding to human glioma cell lines reveals on average
17,000-28,000 binding sites/cell.sup.45. Molecular analysis using
probes specific for IL-13R.alpha.2 mRNA fail to demonstrate
expression of the glioma-specific receptor by normal brain elements
in all CNS anatomic locations.sup.42; 43. Furthermore,
autoradiography with radiolabeled IL-13 failed to demonstrate
detectable specific IL-13 binding in the CNS, suggesting that the
shared IL13R.alpha.1/IL-4.beta./.gamma.c receptor is also not
expressed at detectable levels in the CNS.sup.46. These findings
were independently verified using immunohistochemical techniques on
non-pathologic brain sections with antibodies specific for
IL-13R.alpha.1 and IL-4.beta..sup.54. Thus IL-13R.alpha.2 stands as
the most specific and ubiquitously expressed cell-surface target
for glioma described to date.
[0010] As a strategy to exploit the glioma-specific expression of
IL-13R.alpha.2 in the CNS, molecular constructs of the IL-13
cytokine have been described that fuse various cytotoxins
(Pseudomonas exotoxin and Diptheria toxin) to its carboxyl
terminal.sup.55-58. Internalization of these toxins upon binding to
IL-13 receptors is the basis of the selective toxicity of these
fusion proteins. These toxins display potent cytotoxicity towards
glioma cells in vitro at picomolar concentrations.sup.55. Human
intracranial glioma xenografts in immunodeficient mice can be
eliminated by intratumor injection of the IL-13-toxin fusion
protein without observed toxicities.sup.55. These studies support
the initiation of clinical investigation utilizing IL-13-directed
immunotoxins loco-regionally for malignant glioma.
[0011] However, the binding of IL-13-based cytotoxins to the
broadly expressed IL-13R.alpha.1/IL-4.beta./.gamma.c receptor
complex has the potential of mediating untoward toxicities to
normal tissues outside the CNS, and thus limits the systemic
administration of these agents. IL-13 has been extensively
dissected at the molecular level: structural domains of this
cytokine that are important for associating with individual
receptor subunits have been mapped.sup.55; 58 Consequently,
selected amino acid substitutions in IL-13 have predictable effects
on the association of this cytokine with its receptor subunits.
Amino acid substitutions in IL-13's alpha helix A, in particular at
amino acid 13, disrupt its ability to associate with IL-4.beta.,
thereby selectively reducing the affinity of IL-13 to the
IL-13R.alpha.1/IL-4.beta./.gamma.c receptor by a factor of
five.sup.55; 57; 58 Surprisingly, binding of mutant IL-13(E13Y) to
IL-13R.alpha.2 was not only preserved but increased relative to
wild-type IL-13 by 50-fold. Thus, minimally altered IL-13 analogs
can simultaneously increase IL-13's specificity and affinity for
glioma cells via selective binding to IL-13R.alpha.2 relative to
normal tissues bearing IL-13R.alpha.1/IL-4.beta./.gamma.c
receptors.
[0012] Malignant gliomas represent a clinical entity that is highly
attractive for immunotherapeutic intervention since 1) most
patients with resection and radiation therapy achieve a state of
minimal disease burden and 2) the anatomic location of these tumors
within the confines of the CNS make direct loco-regional
administration of effector cells possible. At least two pathologic
studies have demonstrated that the extent of perivascular
lymphocytic infiltration in malignant gliomas correlates with an
improved prognosis.sup.59-61. Animal model systems have established
that glioma-specific T cells, but not lymphokine-activated killer
(LAK) cells, can mediate the regression of intracerebrally
implanted gliomas.sup.62-71. T cells, unlike LAK cells, have the
capacity to infiltrate into brain parenchyma and thus can target
infiltrating tumor cells that may be distant from the primary
tumor. Despite these findings, there is a substantial body of
evidence that gliomas actively subvert immune destruction,
primarily by the elaboration of immunosuppressive cytokines
(TGF-.beta.2) and prostaglandins, which, inhibit the
induction/amplification of glioma-reactive T cell
responses.sup.72-74. These findings have prompted the evaluation of
ex vivo expanded anti-glioma effector cells for adoptive therapy as
a strategy to overcome tumor-mediated limitations of generating
responses in vivo.
[0013] At least ten pilot studies involving the administration of
ex vivo activated lymphocytes to malignant glioma resection
cavities have been reported to date.sup.75-85. Despite the variety
of effector cell types (LAK, TILs, alloreactive CTLs), their
heterogeneous composition/variability of composition from patient
to patient, and the often modest in vitro reactivity of these
effector cells towards glioma targets, these studies, in aggregate,
report an approximate 50% response rate in patients with
recurrent/refractory disease with anecdotal long-term survivors.
These studies support the premise that a superior clinical effect
of cellular immunotherapy for glioma might be expected with
homogenous highly potent effector cells.
[0014] These pilot studies also report on the safety and
tolerability of direct administration of ex vivo activated
lymphocytes and interleukin-2 (IL-2), a T cell growth factor, into
the resection cavity of patients with malignant glioma.sup.75; 76;
78; 82; 86-92 Even at large individual cell doses (>10.sup.9
cells/dose), as well as high cumulative cell doses
(>27.times.10.sup.9 cells), toxicities are modest, and typically
consist of grade II or less transient headache, nausea, vomiting
and fever. As noted above, these studies also employed the
co-administration of rhIL-2 to support the in vivo survival of
transferred lymphocytes. Multiple doses given either concurrently
with lymphocytes or sequentially after lymphocyte administration
were tolerated at doses as high as 1.2.times.10.sup.6 IU/dose for
12-dose courses of IL-2 delivered every 48-hours.
[0015] Based on the findings outlined above, strategies to improve
the anti-tumor potency of lymphocyte effector cells used in glioma
immunotherapy are under development. One approach utilizes
bi-specific antibodies capable of co-localizing and activating T
lymphocytes via an anti-CD3 domain with glioma targets utilizing an
epidermal growth factor receptor (EGFR) binding domain.sup.93-96.
Preliminary clinical experience with this bi-specific antibody in
combination with autologous lymphocytes suggests that T cells are
activated in situ in the resection cavity. Targeting infiltrating
tumor cells within the brain parenchyma, however, is a potentially
significant limitation of this approach. T cells might have
significantly increased anti-glioma activity if they are specific
for target antigens expressed by gliomas. A growing number of human
genes encoding tumor antigens to which T lymphocytes are reactive
have been cloned, including the SART-1 gene, which appears to be
expressed by nearly 75% of high-grade gliomas.sup.97. Both
dendritic cell-based in vitro cell culture techniques, as well as
tetramer-based T cell selection technologies are making feasible
the isolation of antigen-specific T cells for adoptive therapy.
Since antigens like SART-1 are recognized by T cells in the context
of restricting HLA alleles, antigen-specific approaches will
require substantial expansion in the number of antigens and
restricting HLA alleles capable of presenting these antigens to be
broadly applicable to the general population of glioma
patients.
[0016] Chimeric antigen receptors engineered to consist of an
extracellular single chain antibody (scFvFc) fused to the
intracellular signaling domain of the T cell antigen receptor
complex zeta chain (scFvFc:.zeta.) have the ability, when expressed
in T cells, to redirect antigen recognition based on the monoclonal
antibody's specificity.sup.98. The design of scFvFc:.zeta.
receptors with target specificities for tumor cell-surface epitopes
is a conceptually attractive strategy to generate antitumor immune
effector cells for adoptive therapy as it does not rely on
pre-existing anti-tumor immunity. These receptors are "universal"
in that they bind antigen in a MHC independent fashion, thus, one
receptor construct can be used to treat a population of patients
with antigen-positive tumors. Several constructs for targeting
human tumors have been described in the literature including
receptors with specificities for Her2/Neu, CEA, ERRB-2, CD44v6, and
epitopes selectively expressed on renal cell carcinoma.sup.98-104.
These epitopes all share the common characteristic of being
cell-surface moieties accessible to scFv binding by the chimeric T
cell receptor. In vitro studies have demonstrated that both CD4+
and CD8+ T cell effector functions can be triggered via these
receptors. Moreover, animal models have demonstrated the capacity
of adoptively transferred scFvFc:.zeta. expressing T cells to
eradicate established tumors.sup.105. The function of primary human
T cells expressing tumor-specific scFvFc:.zeta. receptors have been
evaluated in vitro; these cells specifically lyse tumor targets and
secrete an array of pro-inflammatory cytokines including IL-2, TNF,
IFN-.gamma., and GM-CSF.sup.104. Phase I pilot adoptive therapy
studies are underway utilizing autologous scFvFc:.zeta.-expressing
T cells specific for HIV gp120 in HIV infected individuals and
autologous scFvFc:.zeta.-expressing T cells with specificity for
TAG-72 expressed on a variety of adenocarcinomas, including breast
and colorectal adenocarcinoma.
[0017] Investigators at City of Hope have engineered a
CD20-specific scFvFc:.zeta. receptor construct for the purpose of
targeting CD20+B-cell malignancy and an L1-CAM-specific chimeric
immunoreceptor for targeting neuroblastoma.sup.106. Preclinical
laboratory studies have demonstrated the feasibility of isolating
and expanding from healthy individuals and lymphoma patients CD8+
CTL clones that contain a single copy of unrearranged chromosomally
integrated vector DNA and express the CD20-specific scFvFc:.zeta.
receptor.sup.107. To accomplish this, purified linear plasmid DNA
containing the chimeric receptor sequence under the transcriptional
control of the CMV immediate/early promoter and the NeoR gene under
the transcriptional control of the SV40 early promoter was
introduced into activated human peripheral blood mononuclear cells
by exposure of cells and DNA to a brief electrical current, a
procedure called electroporation. Utilizing selection, cloning, and
expansion methods currently employed in FDA-approved clinical
trials at the Fred Hutchinson Cancer Research Center, Seattle,
Wash., gene modified CD8+ CTL clones with CD20-specific cytolytic
activity have been generated from each of six healthy volunteers in
15 separate electroporation procedures. These clones when
co-cultured with a panel of human CD20+ lymphoma cell lines
proliferate, specifically lyse target cells, and are stimulated to
produce cytokines.
SUMMARY OF THE INVENTION
[0018] The present invention relates to chimeric transmembrane
immunoreceptors, named "zetakines," comprised of an extracellular
domain comprising a soluble receptor ligand linked to a support
region capable of tethering the extracellular domain to a cell
surface, a transmembrane region and an intracellular signaling
domain. Zetakines, when expressed on the surface of T lymphocytes,
direct T cell activity to those cells expressing a receptor for
which the soluble receptor ligand is specific. Zetakine chimeric
immunoreceptors represent a novel extension of antibody-based
immunoreceptors for redirecting the antigen specificity of T cells,
with application to treatment of a variety of cancers, particularly
via the autocrine/paracrine cytokine systems utilized by human
malignancy.
[0019] In one preferred embodiment exploiting the tumor-restricted
expression of IL-13R.alpha.2 by malignant glioma and renal cell
carcinoma as a target for cellular immunotherapy, a mutant of the
IL-13 cytokine, IL-13(E13Y), having selective high-affinity binding
to IL-13R.alpha.2 has been converted into a type I transmembrane
chimeric immunoreceptor capable of redirecting T cell antigen
specificity to IL-13R.alpha.2-expressing tumor cells. This
embodiment of the zetakine consists of extracellular IL-13(E13Y)
fused to human IgG4 Fc, transmembrane CD4, and intracellular T cell
antigen receptor CD3 complex zeta chain. Analogous immunoreceptors
can be created that are specific to any of a variety of cancer cell
types that selectively express receptors on their cell surfaces,
for which selective ligands are known or can be engineered.
[0020] Bulk lines and clones of human T cells stably transformed to
express such an immunoreceptor display redirected cytolysis of the
cancer cell type to which they are specific, while showing
negligible toxicity towards non-target cells. Such engineered T
cells are a potent and selective therapy for malignancies,
including difficult to treat cancers such as glioma.
BRIEF DESCRIPTION OF THE FIGURES
[0021] FIG. 1: Results of a Western Blot showing that the
IL13zetakine Chimeric Immunoreceptor is expressed as an intact
glycosylated protein in Jurkat T cells.
[0022] FIG. 2: Results of flow cytometric analysis showing that
expressed IL13zetakine chimeric immunoreceptor trafficks to the
cell-surface as a type I transmembrane protein.
[0023] FIG. 3: Results of flow cytometric analysis showing the cell
surface phenotype of a representative primary human
IL13zetakine.sup.+ CTL clone.
[0024] FIG. 4: Results of chromium release assays. FIG. 4A shows
that the IL13zetakine.sup.+ CTL clone acquired glioma-specific
re-directed cytolytic activity, and FIG. 4B shows the profile of
anti-glioma cytolytic activity by primary human IL13zetakine.sup.+
CD8.sup.+ CTL clones was observed in glioma cells generally.
[0025] FIG. 5: Results of in vitro stimulation of cytokine
production, showing that IL13zetakine.sup.+ CTL clones are
activated for cytokine production by glioma stimulator cells.
[0026] FIG. 6: Results of in vitro stimulation of cytokine
production (FIG. 6A, IFN.gamma.; FIG. 6B, TNF.alpha.; FIG. 6C,
GM-CSF), showing the specific inhibition of IL13zetakine.sup.+ CTL
activation for cytokine production by anti-IL13R Mab and
rhIL13.
[0027] FIG. 7: Results of growth studies. FIG. 7A shows that
IL13zetakine.sup.+ CD8.sup.+ CTL cells proliferate upon co-culture
with glioma stimulators, and FIG. 7B shows the inhibition of
glioma-stimulated proliferation of IL13zetakine.sup.+ CD8.sup.+ CTL
cells by rhIL-13.
[0028] FIG. 8: Flow chart of the construction of
IL13zetakine/HyTK-pMG (FIG. 8A, construction fo hsp-IL13-IgG4
(SmP)-hinge-Fe-Zeta; FIG. 8B, construction of IL13-Fc;.zeta.3pMB
Pac; FIG. 8C, construction of Il13/HyTK-pMG).
[0029] FIG. 9: Plasmid map of IL13zetakine/HyTK-pMG.
[0030] FIG. 10: Plasmid map of alternative
IL13zetakine/HyTK-pMG.
[0031] FIG. 11: Schematic diagram showing structure of IL13
zetakine insert.
[0032] FIG. 12: Nucleic acid sequence of a plasmid DNA vector
(upper strand: SEQ ID NO:14; lower strand:SEQ ID NO:16) and the
corresponding amino acid sequence of IL13zetakine (SEQ ID NO:17)
and HyTK (SEQ ID NO:18).
[0033] FIG. 13: Nucleic acid sequence of an alternate plasmid DNA
vector (upper strand: SEQ ID NO:19; lower strand:SEQ ID NO:20) and
the corresponding amino acid sequence of IL13zetakine (SEQ ID
NO:21) and HyTK (SEQ ID NO:22).
[0034] FIG. 14: Nucleic acid sequence of an alternate plasmid DNA
vector (SEQ ID NO:23).
DETAILED DESCRIPTION
[0035] An ideal cell-surface epitope for tumor targeting with
genetically-engineered re-directed T cells would be expressed
solely on tumor cells in a homogeneous fashion and on all tumors
within a population of patients with the same diagnosis. Modulation
and/or shedding of the target molecule from the tumor cell membrane
may also impact on the utility of a particular target epitope for
re-directed T cell recognition. To date few "ideal" tumor-specific
epitopes have been defined and secondary epitopes have been
targeted based on either lack of expression on critical normal
tissues or relative over-expression on tumors. In the case of
malignant glioma, the intracavitary administration of T cells for
the treatment of this cancer permits the expansion of target
epitopes to those expressed on tumor cells but not normal CNS with
less stringency on expression by other tissues outside the CNS. The
concern regarding toxicity from cross-reactivity of tissues outside
the CNS is mitigated by a) the sequestration of cells in the CNS
based on the intracavitary route of administration and b) the low
cell numbers administered in comparison to cell doses typically
administered systemically.
[0036] The IL-13R.alpha.2 receptor stands out as the most
ubiquitous and specific cell-surface target for malignant
glioma.sup.47. Sensitive autoradiographic and immunohistochemical
studies fail to detect IL-13 receptors in the CNS.sup.46; 48.
Moreover, mutation of the IL-13 cytokine to selectively bind the
glioma-restricted IL-13R.alpha.2 receptor is a further safeguard
against untoward reactivity of IL-13-directed therapeutics against
IL-13R.alpha.1/IL-4.beta.+normal tissues outside the CNS.sup.55;
57. The potential utility of targeting glioma IL-13R.alpha.2 the
design and testing of a novel engineered chimeric immunoreceptor
for re-directing the specificity of T cells that consists of an
extracellular IL-13 mutant cytokine (E13Y) tethered to the plasma
membrane by human IgG4 Fc which, in turn, is fused to CD4.TM. and
the cytoplasmic tail of CD3 zeta. This chimeric immunoreceptor has
been given the designation of "IL-13 zetakine." The IL-13R.alpha.2
receptor/IL-13(E13Y) receptor-ligand pair is an excellent guide for
understanding and assessing the suitability of receptor-ligand
pairs generally for use in zetakines. An ideal zetakine comprises
an extracellular soluble receptor ligand having the properties of
IL-13(E13Y) (specificity for a unique cancer cell surface receptor,
in vivo stability due to it being derived from a
naturally-occurring soluble cell signal molecule, low
immunogenicity for the same reason). The use of soluble receptor
ligands as distinct advantages over the prior art use of antibody
fragments (such as the scFvFc immunoreceptors) or cell adhesion
molecules, in that soluble receptor ligands are more likely to be
stable in the extracellular environment, non-antigenic, and more
selective.
[0037] Chimeric immunoreceptors according to the present invention
comprise an extracellular domain comprised of a soluble receptor
ligand linked to an extracellular support region that tethers the
ligand to the cell surface via a transmembrane domain, in turn
linked to an intracellular receptor signaling domain. Examples of
suitable soluble receptor ligands include autocrine and paracrine
growth factors, chemokines, cytokines, hormones, and engineered
artificial small molecule ligands that exhibit the required
specificity. Natural ligand sequences can also be engineered to
increase their specificity for a particular target cell. Selection
of a soluble receptor ligand for use in a particular zetakine is
governed by the nature of the target cell, and the qualities
discussed above with regard to the IL-13(E13Y) molecule, a
preferred ligand for use against glioma. Examples of suitable
support regions include the constant (Fc) regions of immunoglobins,
human CD8.alpha., and artificial linkers that serve to move the
targeting moiety away from the cell surface for improved access to
receptor binding on target cells. A preferred support region is the
Fc region of an IgG (such as IgG4). Examples of suitable
transmembrane domains include the transmembrane domains of the
leukocyte CD markers, preferably that of CD8. Examples of
intracellular receptor signaling domains are those of the T cell
antigen receptor complex, preferably the zeta chain of CD3 also
Fc.gamma. RIII costimulatory signaling domains, CD28, DAP10, CD2,
alone or in a series with CD3zeta.
[0038] In the IL-13 zetakine embodiment, the human IL-13 cDNA
having the E13Y amino acid substitution was synthesized by PCR
splice overlap extension. A full length IL-13 zetakine construct
was assembled by PCR splice overlap extension and consists of the
human GM-CSF receptor alpha chain leader peptide,
IL-13(E13Y)-Gly-Gly-Gly, human IgG4 Fc, human CD4.TM., and human
cytoplasmic zeta chain. This cDNA construct was ligated into the
multiple cloning site of a modified pMG plasmid under the
transcriptional control of the human Elongation Factor-1alpha
promoter (Invivogen, San Diego). This expression vector
co-expresses the HyTK cDNA encoding the fusion protein HyTK that
combines in a single molecule hygromycin phosphotransferase
activity for in vitro selection of transfectants and HSV thymidine
kinase activity for in vivo ablation of cells with ganciclovir from
the CMV immediate/early promoter. Western blot of whole cell Jurkat
lysates pre-incubated with tunicamycin, an inhibitor of
glycosylation, with an anti-zeta antibody probe demonstrated that
the expected intact 56-kDa chimeric receptor protein is expressed.
This receptor is heavily glycosylated consistent with
post-translational modification of the native IL-13
cytokine.sup.108. Flow cytometric analysis of IL-13 zetakine+
Jurkat cells with anti-human IL-13 and anti-human Fc specific
antibodies confirmed the cell-surface expression of the IL-13
zetakine as a type I transmembrane protein.
[0039] Using established human T cell genetic modification methods
developed at City of Hope.sup.107, primary human T cell clones
expressing the IL-13 zetakine chimeric immunoreceptor have been
generated for pre-clinical functional characterization. IL-13
zetakine+ CD8+ CTL clones display robust proliferative activity in
ex vivo expansion cultures. Expanded clones display re-directed
cytolytic activity in 4-hr chromium release assays against human
IL-13R.alpha.2+ glioblastoma cell lines. The level of cytolytic
activity correlates with levels of zetakine expression on T cells
and IL-13R.alpha.2 receptor density on glioma target cells. In
addition to killing, IL-13 zetakine+ clones are activated for
cytokine secretion (IFN-.gamma., TNF-.alpha., GM-CSF). Activation
was specifically mediated by the interaction of the IL-13 zetakine
with the IL-13R.alpha.2 receptor on glioma cells since CTL clones
expressing an irrelevant chimeric immunoreceptor do not respond to
glioma cells, and, since activation can be inhibited in a
dose-dependent manner by the addition to culture of soluble IL-13
or blocking antibodies against IL-13 on T cell transfectants and
IL-13R.alpha.2 on glioma target cells. Lastly, IL-13
zetakine-expressing CD8+ CTL clones proliferate when stimulated by
glioma cells in culture. IL-13 zetakine+ CTL clones having potent
anti-glioma effector activity will have significant clinical
activity against malignant gliomas with limited collateral damage
to normal CNS.
[0040] An immunoreceptor according to the present invention can be
produced by any means known in the art, though preferably it is
produced using recombinant DNA techniques. A nucleic acid sequence
encoding the several regions of the chimeric receptor can prepared
and assembled into a complete coding sequence by standard
techniques of molecular cloning (genomic library screening, PCR,
primer-assisted ligation, site-directed mutagenesis, etc.). The
resulting coding region is preferably inserted into an expression
vector and used to transform a suitable expression host cell line,
preferably a T lymphocyte cell line, and most preferably an
autologous T lymphocyte cell line. A third party derived T cell
line/clone, a transformed humor or xerogenic immunologic effector
cell line, for expression of the immunoreceptor. NK cells,
macrophages, neutrophils, LAK cells, LIK cells, and stem cells that
differentiate into these cells, can also be used. In a preferred
embodiment, lymphocytes are obtained from a patient by
leukopharesis, and the autologous T cells are transduced to express
the zetakine and administered back to the patient by any clinically
acceptable means, to achieve anti-cancer therapy.
[0041] Suitable doses for a therapeutic effect would be between
about 10.sup.6 and about 10.sup.9 cells per dose, preferably in a
series of dosing cycles. A preferred dosing regimen consists of
four one-week dosing cycles of escalating doses, starting at about
10.sup.7 cells on Day 0, increasing incrementally up to a target
dose of about 10.sup.8 cells by Day 5. Suitable modes of
administration include intravenous, subcutaneous, intracavitary
(for example by reservoir-access device), intraperitoneal, and
direct injection into a tumor mass.
[0042] The following examples are solely for the purpose of
illustrating one embodiment of the invention.
Example 1
Construction of an Immunoreceptor Coding Sequence
[0043] The coding sequence for an immunoreceptor according to the
present invention was constructed by de novo synthesis of the
IL13(E13Y) coding sequence using the following primers (see FIG. 8
for a flow chart showing the construction of the immunoreceptor
coding sequence and expression vector):
TABLE-US-00001 IL13P1: EcoRI (SEQ ID NO. 1)
TATGAATTCATGGCGCTTTTGTTGACCACGGTCATTGCTCTCACTTGCCT
TGGCGGCTTTGCCTCCCCAGGCCCTGTGCCTCCCTCTACAGCCCTCAGGT AC IL13P2: (SEQ
ID NO. 2) GTTGATGCTCCATACCATGCTGCCATTGCAGAGCGGAGCCTTCTGGTTCT
GGGTGATGTTGACCAGCTCCTCAATGAGGTACCTGAGGGCTGTAGAGGG AG IL13P3: (SEQ
ID NO. 3) CTCTGGGTCTTCTCGATGGCACTGCAGCCTGACACGTTGATCAGGGATTC
CAGGGCTGCACAGTACATGCCAGCTGTCAGGTTGATGCTCCATACCATGC IL13P4: (SEQ ID
NO. 4) CCTCGATTTTGGTGTCTCGGACATGCAAGCTGGAAAACTGCCCAGCTGAG
ACCTTGTGCGGGCAGAATCCGCTCAGCATCCTCTGGGTCTTCTCGATGGC IL13P5: BamHI
(SEQ ID NO. 5) TCGGATCCTCAGTTGAACCGTCCCTCGCGAAAAAGTTTCTTTAAATGTAA
GAGCAGGTCCTTTACAAACTGGGCCACCTCGATTTTGGTGTCTCGG
[0044] The final sequence (417 bp) was end-digested with
EcoRI-BamHI, and ligated into the plasmid pSK (stratagene, LaJolla,
Calif.) as ligation 312#3. Ligation 312#3 was mutagenized
(stratagene kit, per manufacturer's instructions) to fix a deleted
nucleotide using the primers 5': IL13 312#3 mut5-3
(CAACCTGACAGCTGGCATGTACTGTGCAGCCCTGGAATC (SEQ ID NO. 6)) and
3':IL13 312#3 mut3-5 (GATTCCAGGGCTGCACAGTACATGCCAGCTGTCAGGTTG (SEQ
ID NO. 7)), and ligation 312#3 as a template, to form ligation
348#1 (IL13zetakine/pSK).
[0045] The coding Human GM-CSFR alpha chain Signal Peptide (hsp)
coding sequence was fused to the 5' end of IL13(E13Y) by standard
PCR splice overlap extension. The hsp sequence (101 bp) was
obtained from the template ligation 301 #10 (hsp/pSK) (human GCSF
receptor .alpha.-chain leader sequence from human T cell cDNA),
using the primers 5':19hsp5'
(ATCTCTAGAGCCGCCACCATGCTTCTCCTGGTGACAAGCCTTC (SEQ ID NO. 8)) (XbaI
site highlighted in bold), and 3': hsp-IL13FR
(GAGGGAGGCACAGGGCCTGGGATCAGGAGGAATG (SEQ ID NO. 9)). The IL-13
sequence (371 bp) was obtained using the primers 5': hsp-IL13FF
(CATTCCTCCTGATCCCAGGCCCTGTGCCTCCCTC (SEQ ID NO. 10)) and 3':
IL13-IgG4FR (GGGACCATATTTGGACTCGTTGAACCGTCCCTCGC (SEQ ID NO. 11)),
and ligation 312#3 as template. Fusion was achieved using the 101
bp hsp sequence and 371 bp IL13 sequence thus obtained, and the
primers 5': 19hsp5' and 3': IL13-IgG4FR, to yield a 438 bp fusion
hsp-IL13 sequence.
[0046] A sequence encoding the IgG4 Fc region IgG4m:zeta was fused
to the 3' end of the hsp-IL13 fusion sequence using the same
methods. The IgG4m:zeta sequence (1119 bp) was obtained using the
primers 5': IL13-IgG4FF (GCGAGGGACGGTTCAACGAGTCCAAATATGGTCCC (SEQ
ID NO. 12)) and 3': ZetaN3' (ATGCGGCCGCTCAGCGAGGGGGCAGG (SEQ ID NO.
13)) (NotI site highlighted in bold), using the sequence R9.10
(IgG4mZeta/pSK) as template. The 1119 bp IgG4m:zeta sequence was
fused to the hsp-IL13 fusion sequence using the respective
sequences as templates, and the primers 5': 19hsp5' and 3':
ZetaN3', to yield a 1522 bp hsp-IL13-IgG4m:zeta fusion sequence.
The ends were digested with XbaI-NotI, and ligated into pSK as
ligation 351#7, to create the plasmid IL13zetakine/pSK (4464
bp).
Example 2
Construction of Expression Vector
[0047] An expression vector containing the IL13 zetakine coding
sequence was created by digesting the IL13zetakine/pSK of Example 1
with XbaI-NotI, and creating blunt ends with Klenow, and ligating
the resulting fragment into the plasmid pMG Pac (Invirogen) (first
prepared by opening with SgrAI, blunting with Klenow, and
dephosphorylation with SAP), to yield the plasmid IL13zetakine/pMG.
See FIG. 8. The hygromycin resistance region of IL13zetakine/pMG
was removed by digestion with NotI-NheI, and replaced by the
selection/suicide fusion HyTK, obtained from plasmid CE7RIHyTK-pMG
(Jensen, City of Hope) by digestion with NotI-NheI, to create the
expression vector IL13zetakine/HyTK-pMG (6785 bp). This plasmid
comprises the Human Elongation Factor-1.alpha. promoter (hEF1p) at
bases 6-549, the IL13zetakine coding sequence at bases 692-2185,
the Simian Virus 40 Late polyadenylation signal (Late SV40pAN) at
bases 2232-2500, a minimal E. coli origin of replication (Ori
ColE1) at bases 2501-3247, a synthetic poly A and Pause site (SpAN)
at bases 3248-3434, the Immeate-early CMV enhancer/promoter (h
CMV-1Aprom) at bases 3455-4077, the Hygromycin resistance-Thymidine
kinase coding region fusion (HyTK) at bases 4259-6334, and the
bovine growth hormone polyadenylation signal and a transcription
pause (BGh pAn) at bases 6335-6633. The plasmid has a PacI
linearization site at bases 3235-3242. The hEF1p and IL13zetakine
elements derived from IL13zetakine/pMG, and the remaining elements
derived from CE7R/HyTk-pMG (and with the exception of the HyTK
element, ultimately from the parent plasmid pMGAPac). In sum,
IL13zetakine/HyTK-pMG is a modified pMG backbone, expressing the
IL13zetakine gene from the hEF1 promoter, and the HyTK fusion from
the h CMV-1A promoter. A map of the plasmid IL13zetakine/HyTK-pMG
appears in FIG. 9. The full nucleic acid sequence of the plasmid is
shown in FIG. 12. The sequence of an IL13zetakine insert is given
as SEQ ID NO:15, below. See also FIG. 11.
TABLE-US-00002 (SEQ ID NO: 15)
atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagc
attcctcctgatcccaggccctgtgcctccctctacagccctcaggtacc
tcattgaggagctggtcaacatcacccagaaccagaaggctccgctctgc
aatggcagcatggtatggagcatcaacctgacagctggcatgtactgtgc
agccctggaatccctgatcaacgtgtcaggctgcagtgccatcgagaaga
cccagaggatgctgagcggattctgcccgcacaaggtotcagctgggcag
ttttccagcttgcatgtccgagacaccaaaatcgaggtggcccagtttgt
aaaggacctgctcttacatttaaagaaactttttcgcgagggacggttca
acgagtccaaatatggtcccccatgcccaccatgcccagcacctgagttc
ctggggggaccatcagtcttcctgttccccccaaaacccaaggacactct
catgatctcccggacccctgaggtcacgtgcgtggtggtggacgtgagcc
aggaagaccccgaggtccagttcaactggtacgtggatggcgtggaggtg
cataatgccaagacaaagccgcgggaggagcagttcaacagcacgtaccg
tgtggtcagcgtcctcaccgtcctgcaccaggactggctgaacggcaagg
agtacaagtgcaaggtctccaacaaaggcctcccgtcctccatcgagaaa
accatctccaaagccaaagggcagccccgagagccacaggtgtacaccct
gcccccatcccaggaggagatgaccaagaaccaggtcagcctgacctgcc
tggtcaaaggcttctaccccagcgacatcgccgtggagtgggagagcaat
gggcagccggagaacaactacaagaccacgcctcccgtgctggactccga
cggctccttcttcctctacagcaggctaaccgtggacaagagcaggtggc
aggaggggaatgtcttctcatgctccgtgatgcatgaggctctgcacaac
cactacacacagaagagcctctccctgtccctaggtaaaatggccctgat
tgtgctggggggcgtcgccggcctcctgcttttcattgggctaggcatct
tcttcagagtgaagttcagcaggagcgcagacgcccccgcgtaccagcag
ggccagaaccagctctataacgagctcaatctaggacgaagagaggagta
cgatgttttggacaagagacgtggccgggaccctgagatggggggaaagc
cgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagat
aagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggag
gggcaaggggcacgatggcctttaccagggtctcagtacagccaccaagg
acacctacgacgcccttcacatgcaggccctgccccctcgc.
Example 3
Expression of the Immunoreceptor
[0048] Assessment of the integrity of the expressed construct was
first delineated by Wester blot probed with an anti-zeta antibody
of whole cell lysates derived from Jurkat T cell stable
transfectants.sup.107 cocultured in the presence or absence of
tunicamycin, an inhibitor of glycosylation. FIG. 1. Jurkat T cell
stable transfectants (Jurkat-IL13-pMG bulk line) were obtained by
electroporating Jurkat T cells with the IL13zetakine/HyTK-pMG
expression vector, followed by selection and expansion of positive
transfectants. 2.times.10.sup.6 cells from the Jurkat-IL13-pMG bulk
line were plated per well in a 24-well plate with or without 5
.mu.g/ml, 10 .mu.g/ml, or 20 .mu.g/ml Tunicamycin. The plate was
incubated at 37.degree. C. for 22 hrs. Cells were harvested from
each well, and each sample was washed with PBS and resuspended in
50 .mu.l RIPA buffer (PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS) containing 1 tablet/10ml Complete Protease Inhibitor Cocktail
(Boehringer Mannheim, Indianapolis, Ind.). Samples were incubated
on ice for 30 minutes then disrupted by aspiration with syringe
with 21 gauge needle then incubated on ice for an additional 30
minutes before being centrifuged at 4.degree. C. for 20 minutes at
14,000 rpm. Samples of centrifuged lysate supernatant were
harvested and boiled in an equal volume of sample buffer under
reducing conditions, then subjected to SDS-PAGE electrophoresis on
a 12% acrylamide gel. Following transfer to nitrocellulose,
membrane was allowed to dry O/N at 4.degree. C. Next morning,
membrane was blocked in a Blotto solution containing 0.04 gm/ml
non-fat dried milk in T-TBS (0.02% Tween 20 in Tris buffered saline
pH 8.0) for 1 hour. Membrane was then incubated with primary mouse
anti-human CD3.zeta. monoclonal antibody (Pharmingen, San Diego,
Calif.) at a concentration of 1 .mu.g/ml for 2 hours, washed, and
then incubated with a 1:3000 dilution (in Blotto solution) of goat
anti-mouse IgG alkaline phosphatase conjugated secondary antibody
(Bio-Rad ImmunoStar Kit, Hercules, Calif.) for 1 hour. Prior to
developing, membrane was washed 4 additional times in T-TBS, and
then incubated with 3 ml of phosphatase substrate solution (Biorad
ImmunoStar Kit, Hercules, Calif.) for 5 minutes at room
temperature. Membrane was then covered with plastic, and exposed to
x-ray film. Consistant with the known glycosylation pattern of
wild-type human IL-13, the electrophoretic mobility of expressed
IL-13(E13Y) zetakine is demonstrative of a heavily glycosylated
protein which, when expressed in the presence of tunicamycin, is
reduced to an amino acid backbone of approximately 54 kDa.
[0049] The IL-13(E13Y) zetakine traffics to the cell surface as a
homodimeric type I transmembrane protein, as evidenced by flow
cytometric analysis of transfectants with a phycoerythrin
(PE)-conjugated anti human-IL13 monoclonal antibody and a
fluorescein isothiocyanate (FITC)-conjugated mouse anti-human Fc
(gamma) fragment-specific F(ab').sub.2 antibody. FIG. 2. Jurkat
IL13zetakine-pMG transfectants were stained with anti-human
Fc(FITC) antibody (Jackson ImmunoResearch, West Grove, Pa.),
recombinant human IL13R.alpha.2/human IgG1 chimera (R&D
Systems, Minneapolis, Minn.) followed by FITC-conjugated anti
human-IgG1 monoclonal antibody (Sigma, St. Louis, Mo.), and an
anti-IL13(PE) antibody (Becton Dickinson, San Jose, Calif.) for
analysis of cell surface chimeric receptor expression. Healthy
donor primary cells were also stained with FITC-conjugated
anti-CD4, anti-CD8, anti-TCR, and isotype control monoclonal
antibodies (Becton Dickinson, San Jose, Calif.) to assess cell
surface phenotype. For each stain, 10.sup.6 cells were washed and
resuspended in 100 .mu.l of PBS containing 2% FCS, 0.2 mg/ml
NaN.sub.3, and 5 .mu.l of stock antibody. Following a 30 minute
incubation at 4.degree. C., cells were washed twice and either
stained with a secondary antibody, or resuspended in PBS containing
1% paraformaldehyde and analyzed on a FACSCaliber cytometer.
Example 4
Binding of IL13(E13Y) Zetakine to IL13R.alpha.2 Receptor
[0050] IL-13(E13Y), tethered to the cell membrane by human IgG4 Fc
(i.e., IL13(E13Y) zetakine), is capable of binding to its target
IL13R.alpha.2 receptor as assessed by flow cytometric analysis
using soluble IL13R.alpha.2-Fc fusion protein. FIG. 3. Cloned human
PBMC IL13zetakine-pMG transfectants were obtained by
electroporating PBMC with the IL13zetakine/HyTK-pMG expression
vector, followed by selection and expansion of positive
transfectants.sup.107. IL13zetakine.sup.+ CTL clonal cells were
stained with a fluorescein isothiocyanate (FITC)-conjugated mouse
anti-human Fc (gamma) fragment-specific F(ab').sub.2 (Jackson
ImmunoResearch, West Grove, Pa.), recombinant human
IL13R.alpha.2/human IgG1 chimera (R&D Systems, Minneapolis,
Minn.) followed by FITC-conjugated anti human-IgG1 monoclonal
antibody (Sigma, St. Louis, Mo.), and a phycoerythrin
(PE)-conjugated anti human-IL13 monoclonal antibody (Becton
Dickinson, San Jose, Calif.) for analysis of cell surface chimeric
receptor expression. Healthy donor primary cells were also stained
with FITC-conjugated anti-CD4, anti-CD8, anti-TCR, and isotype
control monoclonal antibodies (Becton Dickinson, San Jose, Calif.)
to assess cell surface phenotype. For each stain, 10.sup.6 cells
were washed and resuspended in 100 .mu.l of PBS containing 2% FCS,
0.2 mg/ml NaN.sub.3, and 5 .mu.l of antibody. Following a 30 minute
incubation at 4.degree. C., cells were washed twice and either
stained with a secondary antibody, or resuspended in PBS containing
1% paraformaldehyde and analyzed on a FACSCaliber cytometer.
[0051] Next, the immunobiology of the IL-13(E13Y) zetakine as a
surrogate antigen receptor for primary human T cells was evaluated.
Primary human T cells were electroporated with the plasmid
expression vector. Positive transformants were selected with
hygromycin, cloned in limiting dilution, then expanded by recursive
stimulation cycles with OKT3, IL-2 and irradiated feeder cells.
Clones demonstrating IL 13zetakine expression by Western blot and
FACS were then subjected to functional evaluation in 4-hr chromium
release assays against a variety of IL-13.alpha.2.sup.+/CD20.sup.-
glioma cell lines (U251, SN-B19, U138), and the
IL-13.alpha..sup.-/CD20.sup.+ B cell lymphocyte line Daudi). These
tests showed that IL13zetakine conferred cytolytic activity that
was specific for glioma cells (FIG. 4a), and that this specific
cytolytic activity is present for glioma cells as a class (FIG.
4b). The cytolytic activity of MJ-IL13-pMG clones was assayed by
employing .sup.51Cr-labeled SN-B19, U251, and U138 glioma cell
lines (IL13.alpha.2+/CD20-) and Daudi (CD20+/IL13.alpha.2-) as
targets. MJ-IL13 effectors were assayed 8-12 days following
stimulation. Effectors were harvested, washed, and resuspended in
assay media: 2.5.times.10.sup.5, 1.25.times.10.sup.5,
2.5.times.10.sup.4, and 5.times.10.sup.3 effectors were cultured in
triplicate at 37.degree. C. for 4 hours with 5.times.10.sup.3
target cells in 96-well V-bottom microtiter plates. After
incubation, 100 .mu.l aliquots of cell-free supernatant were
harvested and .sup.51Cr in the supernatants was assayed with a
.gamma.-counter. Percent specific cytolysis was calculated as
follows:
( Experimental 51 Cr release ) - ( control 51 Cr release ) (
Maximum 51 Cr release ) - ( control 51 Cr release ) .times. 100
##EQU00001##
Control wells contained target cells incubated in the presence of
target cells alone. Maximum .sup.51Cr release was determined by
measuring the .sup.51Cr released by labeled target cells in the
presence of 2% SDS. Bulk lines of stabley transfected human T cells
consisting of approximately 40% IL-13(E13Y) zetakine.sup.+
TCR.alpha./.beta..sup.+ lymphocytes displayed re-directed cytolysis
specific for 13R.alpha.2.sup.+ glioma targets in 4-hr chromium
release assays (>50% specific lysis at E:T ratios of 25:1), with
negligable acitivity against IL-13R.alpha.2-targets (<8%
specific lysis at E:T ratios of 25:1). IL-13(E13Y)
zetakine.sup.+CD8.sup.+TCR.alpha./.beta..sup.+ CTL clones selected
on the basis of high-level binding to anti-IL-13 antibody also
display redirected IL13R.alpha.2-specific glioma cell killing. FIG.
4b.
[0052] IL-13 zetakine-expressing CD8.sup.+ CTL clones are activated
and proliferate when stimulated by glioma cells in culture. FIGS.
5-7. MJ-IL13-pMG Cl. F2 responder cells expressing the IL13
zetakine were evaluated for receptor-mediated triggering of
IFN.gamma., GM-CSF, and TNF.alpha. production in vitro.
2.times.10.sup.6 responder cells were co-cultured in 24-well tissue
culture plates with 2.times.10.sup.5 irradiated stimulator cells
(Daudi, Fibroblasts, Neuroblastoma 10HTB, and glioblastoma U251) in
2 ml total. Blocking rat anti-human-IL13 monoclonal antibody
(Pharmingen, San Diego, Calif.), recombinant human IL13 (R&D
Systems, Minneapolis, Minn.), and IL13R.alpha.2-specific goat IgG
(R&D Systems, Minneapolis, Minn.) were added to aliquots of
U251 stimulator cells (2.times.10.sup.5/ml) at concentrations of 1
ng/ml, 10 ng/ml, 100 ng/ml, and 1 .mu.g/ml, 30 minutes prior to the
addition of responder cells. Plates were incubated for 72 hours at
37.degree. C., after which time culture supernatants were
harvested, aliquoted, and stored at -70.degree. C. ELISA assays for
IFN.gamma., GM-CSF, and TNF.alpha. were carried out using the
R&D Systems (Minneapolis, Minn.) kit per manufacturer's
instructions. Samples were tested in duplicate wells undiluted or
diluted at 1:5 or 1:10. The developed ELISA plate was evaluated on
a microplate reader and cytokine concentrations determined by
extrapolation from a standard curve. Results are reported as
picograms/ml, and show strong activation for cytokine production by
glioma stimulator cells. FIG. 5, FIG. 6.
[0053] Lastly, IL-2 independent proliferation of IL13zetakine.sup.+
CD8.sup.+ CTL was observed upon co-cultivation with glioma
stimulators (FIG. 7a), but not with IL13 R.alpha.2 stimulators.
Proliferation was inhibited by the addition of rhIL-13 antibody
(FIG. 7b), showing that the observed proliferation was dependant on
binding of zetakine to the IL-13R.alpha.2 glioma cell-specific
receptor.
Example 5
Preparation of IL-13 zetakine.sup.+ T Cells Suitable for
Therapeutic Use
[0054] The mononuclear cells are separated from heparinized whole
blood by centrifugation over clinical grade Ficoll (Pharmacia,
Uppsula, Sweden). PBMC are washed twice in sterile phosphate
buffered saline (Irvine Scientific) and suspended in culture media
consisting of RPMI 1640 HEPES, 10% heat inactivated FCS, and 4 mM
L-glutamine. T cells present in patient PBMC are polyclonally
activated by addition to culture of Orthoclone OKT3 (30 ng/ml).
Cell cultures are then incubated in vented T75 tissue culture
flasks in the study subject's designated incubator. Twenty-four
hours after initiation of culture rhIL-2 is added at 25 U/ml.
[0055] Three days after the initiation of culture PBMC are
harvested, centrifuged, and resuspended in hypotonic
electroporation buffer (Eppendorf) at 20.times.10.sup.6 cells/ml.
25 .mu.g of the plasmid IL13zetakine/HyTK-pMG of Example 3,
together with 400 .mu.l of cell suspension, are added to a sterile
0.2 cm electroporation cuvette. Each cuvette is subjected to a
single electrical pulse of 250V/40 .mu.s and again incubated for
ten minutes at RT. Surviving cells are harvested from cuvettes,
pooled, and resuspended in culture media containing 25 U/ml rhIL-2.
Flasks are placed in the patient's designated tissue culture
incubator. Three days following electroporation hygromycin is added
to cells at a final concentration of 0.2 mg/ml. Electroporated PBMC
are cultured for a total of 14 days with media and IL-2
supplementation every 48-hours.
[0056] The cloning of hygromycin-resistant CD8+ CTL from
electroporated OKT3-activated patient PBMC is initiated on day 14
of culture. Briefly, viable patient PBMC are added to a mixture of
100.times.10.sup.6 cyropreserved irradiated feeder PBMC and
20.times.10.sup.6 irradiated TM-LCL in a volume of 200 ml of
culture media containing 30 ng/ml OKT3 and 50 U/ml rhIL-2. This
mastermix is plated into ten 96-well cloning plates with each well
receiving 0.2 ml. Plates are wrapped in aluminum foil to decrease
evaporative loss and placed in the patient's designated tissue
culture incubator. On day 19 of culture each well receives
hygromycin for a final concentration of 0.2 mg/ml. Wells are
inspected for cellular outgrowth by visualization on an inverted
microscope at Day 30 and positive wells are marked for
restimulation.
[0057] The contents of each cloning well with cell growth are
individually transferred to T25 flasks containing 50.times.10.sup.6
irradiated PBMC, 10.times.10.sup.6 irradiated LCL, and 30 ng/mlOKT3
in 25 mls of tissue culture media. On days 1,3,5,7,9,11, and 13
after restimulation flasks receive 50 U/ml rhIL-2 and 15 mls of
fresh media. On day 5 of the stimulation cycle flasks are also
supplemented with hygromycin 0.2 mg/ml. Fourteen days after seeding
cells are harvested, counted, and restimulated in T75 flasks
containing 150.times.10.sup.6 irradiated PBMC, 30.times.10.sup.6
irradiated TM-LCL and 30 ng/ml OKT3 in 50 mls of tissue culture
media. Flasks receive additions to culture of rhIL-2 and hygromycin
as outlined above.
[0058] CTL selected for expansion for possible use in therapy are
analyzed by immunofluorescence on a FACSCalibur housed in CRB-3006
using FITC-conjugated monoclonal antibodies WT/31 (a.beta.TCR), Leu
2a (CD8), and OKT4 (CD4) to confirm the requisite phenotype of
clones (.alpha..beta.TCR+, CD4-, CD8+, and IL13+). Criteria for
selection of clones for clinical use include uniform TCR
.alpha..beta.+, CD4-, CD8+ and IL13+ as compared to isotype control
FITC/PE-conjugated antibody. A single site of plasmid vector
chromosomal integration is confirmed by Southern blot analysis. DNA
from genetically modified T cell clones will be screened with a DNA
probe specific for the plasmid vector. Probe DNA specific for the
HyTK in the plasmid vector is synthesized by random priming with
fluorescein-conjugated dUTP per the manufacture's instructions
(Amersham, Arlington Hts, Ill.). T cell genomic DNA is isolated per
standard technique. Ten micrograms of genomic DNA from T cell
clones is digested overnight at 37.degree. C. then
electrophoretically separated on a 0.85% agarose gel. DNA is then
transferred to nylon filters (BioRad, Hercules, Calif.) using an
alkaline capillary transfer method. Filters are hybridized
overnight with probe in 0.5 M Na.sub.2PO.sub.4, pH 7.2, 7% SDS,
containing 10 .mu.g/ml salmon sperm DNA (Sigma) at 65.degree. C.
Filters are then washed four times in 40 mM Na.sub.2PO.sub.4, pH
7.2, 1% SDS at 65.degree. C. and then visualized using a
chemiluminescence AP-conjugated anti-florescein antibody (Amersham,
Arlington Hts, Ill.). Criteria for clone selection is a single band
unique vector band.
[0059] Expression of the IL-13 zetakine is determined by Western
blot procedure in which chimeric receptor protein is detected with
an anti-zeta antibody. Whole cell lysates of transfected T cell
clones are generated by lysis of 2.times.10.sup.7 washed cells in 1
ml of RIPA buffer (PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS) containing 1 tablet/10 ml Complete Protease Inhibitor Cocktail
(Boehringer Mannheim). After an eighty minute incubation on ice,
aliquots of centrifuged whole cell lysate supernatant are harvested
and boiled in an equal volume of loading buffer under reducing
conditions then subjected to SDS-PAGE electrophoresis on a precast
12% acrylamide gel (BioRad). Following transfer to nitrocellulose,
membranes are blocked in blotto solution containing 0.07 gm/ml
non-fat dried milk for 2 hours. Membranes are washed in T-TBS
(0.05% Tween 20 in Tris buffered saline pH 8.0) then incubated with
primary mouse anti-human CD3.zeta. monoclonal antibody 8D3
(Pharmingen, San Diego, Calif.) at a concentration of 1 .mu.g/ml
for 2 hours. Following an additional four washes in T-TBS,
membranes are incubated with a 1:500 dilution of goat anti-mouse
IgG alkaline phosphatase-conjugated secondary antibody for 1 hour.
Prior to developing, membranes are rinsed in T-TBS then developed
with 30 ml of "AKP" solution (Promega, Madison, Wis.) per the
manufacturer's instructions. Criteria for clone selection is the
presence of a chimeric zeta band.
[0060] CD8+ cytotoxic T cell clones expressing the IL-13 zetakine
chimeric immunoreceptor recognize and lyse human glioblastoma
target cells following interaction of the chimeric receptor with
the cell surface target epitope in a HLA-unrestricted fashion. The
requirements for target IL-13R.alpha.2 epitope expression and class
I MHC independent recognition will be confirmed by assaying each
a.beta.TCR+, CD8+, CD4-, IL-13 zetakine+ CTL clones against
IL-13R.alpha.2+ Daudi cell transfectants and IL-13R.alpha.2- Daudi
cells. T cell effectors are assayed 12-14 days following
stimulation with OKT3. Effectors are harvested, washed, and
resuspended in assay media; and Daudi cell transfectants expressing
IL-13R.alpha.2. 2.5.times.10.sup.5, 1.25.times.10.sup.5,
0.25.times.10.sup.5, and 0.05.times.10.sup.5 effectors are plated
in triplicate at 37.degree. C. for 4 hours with 5.times.10.sup.3
target cells in V-bottom microtiter plates (Costar, Cambridge,
Mass.). After centrifugation and incubation, 100 .mu.L aliquots of
cell-free supernatant is harvested and counted. Percent specific
cytolysis is calculated as:
( Experimental 51 Cr release ) - ( control 51 Cr release ) (
Maximum 51 Cr release ) - ( control 51 Cr release ) .times. 100
##EQU00002##
Control wells contain target cells incubated in assay media.
Maximum .sup.51Cr release is determined by measuring the .sup.51Cr
content of target cells lysed with 2% SDS. Criteria for clone
selection is >25% specific lysis of IL-13R.alpha.2+ Daudi
transfectants at an E:T ratio of 5:1 and a <10% lysis of
parental Daudi at the same E:T ratio.
Example 6
Treatment of Human Glioma Using IL-13 Zetakine-Expressing T
Cells
[0061] T cell clones genetically modified according to Example 5 to
express the IL-13R zetakine chimeric immunoreceptor and HyTK are
selected for: [0062] a. TCR.alpha./.beta..sup.+, CD4.sup.-,
CD8.sup.+, IL-13.sup.+ cell surface phenotype as determined by flow
cytometry. [0063] b. Presence of a single copy of chromosomally
integrated plasmid vector DNA as evidenced by Southern blot. [0064]
c. Expression of the IL-13 zetakine protein as detected by Western
blot. [0065] d. Specific lysis of human IL-13R.alpha.2.sup.+
targets in 4-hr chromium release assays. [0066] e. Dependence on
exogenous IL-2 for in vitro growth. [0067] f. Mycoplasma, fungal,
bacterial sterility and endotoxin levels <5 EU/ml. [0068] g. In
vitro sensitivity of clones to ganciclovir.
[0069] Peripheral blood mononuclear cells are obtained from the
patient by leukapheresis, preferably following recovery from
initial resection surgery and at a time at least three weeks from
tapering off steroids and/or their most recent systemic
chemotherapy. The target leukapheresis mononuclear cell yield is
5.times.10.sup.9 and the target number of hygromycin-resistant
cytolytic T cell clones is 25 with the expectation that at least
five clones will be identified that meet all quality control
parameters for ex-vivo expansion. Clones are cryopreserved and
patients monitored by serial radiographic and clinical
examinations. When recurrence of progression of disease is
documented, patients undergo a re-resection and/or placement of a
reservoir-access device (Omaya reservoir) for delivering T cells to
the tumor resection cavity. Following recovery from surgery and
tapering of steroids, if applicable, the patient commences with T
cell therapy.
[0070] The patient receives a target of at least four one-week
cycles of therapy. During the first cycle, cell dose escalation
proceeds from an initial dose on Day 0 of 10.sup.7 cells, followed
by 5.times.10.sup.7 cells on Day 3 to the target-dose of 10.sup.8
cells on Day 5. Cycle 2 commences as early as one week from
commencement of cycle 1. Those patients demonstrating tumor
regression with residual disease on MRI may have additional courses
of therapy beginning no earlier than Week 7 consisting of
repetition of Cycles 3 and 4 followed by one week of rest/restaging
provided these treatments are well tolerated (max. toxicities
<grade 3) until such time that disease progression or a CR is
achieved based on radiographic evaluation.
[0071] Cell doses are at least a log less than doses given in
studies employing intracavitary LAK cells (individual cell doses of
up to 10.sup.9 and cumulative cell numbers as high as
2.75.times.10.sup.10 have been safety administered), ex vivo
expanded TILs (up to 10.sup.9 cells/dose reported with minimal
toxicity) and allo-reactive lymphocyte (starting cell dose 10.sup.8
with cumulative cell doses up to 51.5.times.10.sup.8) delivered to
a similar patient population.sup.75-85. The rationale for the lower
cell doses as proposed in this protocol is based on the increased
in vitro reactivity/anti-tumor potency of IL-13 zetakine+ CTL
clones compared to the modest reactivity profile of previously
utilized effector cell populations. Low-dose repetitive dosing is
favored to avoid potentially dangerous inflammatory responses that
might occur with single large cell number instillations. Each
infusion will consist of a single T cell clone. The same clone will
be administered throughout a patient's treatment course. On the
days of T cell administration, expanded clones are aseptically
processed by washing twice in 50 cc of PBS then resuspended in
pharmaceutical preservative-free normal saline in a volume that
results in the cell dose for patient delivery in 2 mls. T cells are
instilled over 5-10 minutes. A 2 ml PFNS flush will be administered
over 5 minutes following T cells. Response to therapy is assessed
by brain MRI+/-gandolinium, with spectroscopy.
[0072] Expected side-effects of administration of T cells into
glioma resection cavities typically consist of self-limited nausea
and vomiting, fever, and transient worsening of existing
neurological deficits. These toxicities can be attributed to both
the local inflammation/edema in the tumor bed mediated by T cells
in combination with the action of secreted cytokines. These
side-effects typically are transient and less than grade II in
severity. Should patients experience more severe toxicities it is
expected that decadron alone or in combination with ganciclovir
will attenuate the inflammatory process and ablate the infused
cells. The inadvertent infusion of a cell product that is
contaminated with bacteria or fungus has the potential of mediating
serious or life-threatening toxicities. Extensive pre-infusion
culturing of the cell product is conducted to identify contaminated
tissue culture flasks and minimize this possibility. On the day of
re-infusion, gram stains of culture fluids, as well as, endotoxin
levels are performed.
[0073] Extensive molecular analysis for expression of
IL-13R.alpha.2 has demonstrated that this molecule is
tumor-specific in the context of the CNS.sup.44; 46; 48; 54
Furthermore, the only human tissue with demonstrable IL-13R.alpha.2
expression appears to be the testis.sup.42. This tumor-testis
restrictive pattern of expression is reminiscent of the growing
number of tumor antigens (i.e. MAGE, BAGE, GAGE) expressed by a
variety of human cancers, most notably melanoma and renal cell
carcinoma.sup.109-111. Clinical experience with vaccine and
adoptive T cell therapy has demonstrated that this class of
antigens can be exploited for systemic tumor immunotherapy without
concurrent autoimmune attack of the testis.sup.112-114. Presumably
this selectively reflects the effect of an intact blood-testis
barrier and an immunologically privileged environment within the
testis. Despite the exquisite specificity of the mutant IL-13
targeting moiety, toxicities are theoretically possible if cells
egress into the systemic circulation in sufficient numbers and
recognize tissues expressing the IL-13R.alpha.1/IL-4.beta.
receptor. In light of this remote risk, as well as the possibility
that instilled T cells in some patients may mediate an overly
exuberant inflammatory response in the tumor bed, clones are
equipped with the HyTK gene which renders T cells susceptible to in
vivo ablation with ganciclovir.sup.115-118. Ganciclovir-suicide, in
combination with an intra-patient T cell dose escalation strategy,
helps minimize the potential risk to research participants.
[0074] Side effects associated with therapy (headache, fever,
chills, nausea, etc.) are managed using established treatments
appropriate for the condition. The patient receives ganciclovir if
any new grade 3 or any grade 4 treatment-related toxicity is
observed that, in the opinion of the treating physician, puts that
patient at significant medical danger. Parentally administered
ganciclovir is dosed at 10 mg/kg/day divided every 12 hours. A
14-day course will be prescribed but may be extended should
symptomatic resolution not be achieved in that time interval.
Treatment with ganciclovir leads to the ablation of IL-13
zetakine.sup.+ HyTK.sup.+ CD8.sup.+ CTL clones. Patients should be
hospitalized for the first 72 hours of ganciclovir therapy for
monitoring purposes. If symptoms do not respond to ganciclovir
within 48 hours additional immunosuppressive agents including but
not limited to corticosteroids and cyclosporin may be added at the
discretion of the treating physician. If toxicities are severe,
decadron and/or other immunosuppressive drugs along with
ganciclovir are used earlier at the discretion of the treating
physician.
Example 7
Additional Preferred DNA Vectors
[0075] Additional DNA vectors are shown in FIGS. 13 and 14. Table
I, below contains further information concerning the sequence of
FIG. 13. See FIG. 10 for a map of this vector.
TABLE-US-00003 TABLE I Plasmid DNA Vector Sequence Contents for SEQ
ID NO: 19. Plasmid Location Element Description (bases) hEF1p Human
Elongation Factor-1.alpha. Promoter 6-549 IL13zetakine IL13
cytokine fused to Fc: .zeta. 690-2183 Late SV40pAn Simian Virus 40
Late polyadenylation 2230-2498 signal Ori ColE1 A minimal E. coli
origin of replication 2499-3245 SpAn A synthetic poly A and Pause
site 3246-3432 hCMV-1Aprom Immediate-early CMV enhancer/promoter
3433-4075 HyTK Genetic fusion of the Hygromycin 4244-6319
Resistance and Thymidine Kinase coding regions BGh pAn Bovine
growth hormone polyadenylation 6320-6618 signal and a
transcriptional pause
REFERENCES
[0076] 1. Davis F G, McCarthy B J. Epidemiology of brain tumors.
Curr Opin Neurol. 2000; 13:635-640. [0077] 2. Davis F G, Malinski
N, Haenszel W, et al. Primary brain tumor incidence rates in four
United States regions, 1985-1989: a pilot study. Neuroepidemiology.
1996; 15:103-112. [0078] 3. Smith M A, Freidlin B, Ries L A, Simon
R. Increased incidence rates but no space-time clustering of
childhood astrocytoma in Sweden, 1973-1992: a population-based
study of pediatric brain tumors. Cancer. 2000; 88:1492-1493. [0079]
4. Ahsan H, Neugut A I, Bruce J N. Trends in incidence of primary
malignant brain tumors in USA, 1981-1990. Int J. Epidemiol. 1995;
24:1078-1085. [0080] 5. Ashby L S, Obbens E A, Shapiro W R. Brain
tumors. Cancer Chemother Biol Response Modif. 1999; 18:498-549.
[0081] 6. Davis F G, Freels S, Grutsch J, Barlas S, Brem S.
Survival rates in patients with primary malignant brain tumors
stratified by patient age and tumor histological type: an analysis
based on Surveillance, Epidemiology, and End Results (SEER) data,
1973-1991. J. Neurosurg. 1998; 88:1-10. [0082] 7. Duffner P K,
Cohen M E, Myers M H, Heise H W. Survival of children with brain
tumors: SEER Program, 1973-1980. Neurology. 1986; 36:597-601.
[0083] 8. Davis F G, Freels S, Grutsch J, Barlas S, Brem S.
Survival rates in patients with primary malignant brain tumors
stratified by patient age and tumor histological type: an analysis
based on Surveillance, Epidemiology, and End Results (SEER) data,
1973-1991. J. Neurosurg. 1998; 88:1-10. [0084] 9. Kolles H,
Niedermayer I, Feiden W. Grading of astrocytomas and
oligodendrogliomas. Pathologe. 1998; 19:259-268. [0085] 10.
Huncharek M, Muscat J. Treatment of recurrent high grade
astrocytoma; results of a systematic review of 1,415 patients.
Anticancer Res. 1998; 18:1303-1311. [0086] 11. Loiseau H, Kantor G.
The role of surgery in the treatment of glial tumors. Cancer
Radiother. 2000; 4 Suppl 1:48s-52s. [0087] 12. Palma L. Trends in
surgical management of astrocytomas and other brain gliomas. Forum
(Genova).1998; 8:272-281. [0088] 13. Azizi S A, Miyamoto C.
Principles of treatment of malignant gliomas in adults: an
overview. J. Neurovirol. 1998; 4:204-216. [0089] 14. Shapiro W R,
Shapiro J R. Biology and treatment of malignant, glioma. Oncology
(Huntingt). 1998; 12:233-240. [0090] 15. Chamberlain M C, Kormanik
P A. Practical guidelines for the treatment of malignant gliomas.
West J. Med. 1998; 168:114-120. [0091] 16. Ushio Y. Treatment of
gliomas in adults. Curr Opin Oncol. 1991; 3:467-475. [0092] 17.
Scott J N, Rewcastle N B, Brasher P M, et al. Long-term
glioblastoma multiforme survivors: a population-based study. Can J
Neurol Sci. 1998; 25:197-201. [0093] 18. Finlay J L, Wisoff J H.
The impact of extent of resection in the management of malignant
gliomas of childhood. Childs Nerv Syst. 1999; 15:786-788. [0094]
19. Hess K R. Extent of resection as a prognostic variable in the
treatment of gliomas. J. Neurooncol. 1999; 42:227-231. [0095] 20.
van den Bent M J. Chemotherapy in adult malignant glioma. Front
Radiat Ther Oncol. 1999; 33:174-191. [0096] 21. DeAngelis L M,
Burger P C, Green S B, Cairncross J G. Malignant glioma: who
benefits from adjuvant chemotherapy? Ann Neurol. 1998; 44:691-695.
[0097] 22. Armstrong T S, Gilbert M R. Chemotherapy of
astrocytomas: an overview. Semin Oncol Nurs. 1998; 14:18-25. [0098]
23. Prados M D, Russo C. Chemotherapy of brain tumors. Semin Surg
Oncol. 1998; 14:88-95. [0099] 24. Prados M D, Scott C, Curran W J,
Nelson D F, Leibel S, Kramer S. Procarbazine, lomustine, and
vincristine (PCV) chemotherapy for anaplastic astrocytoma: A
retrospective review of radiation therapy oncology group protocols
comparing survival with carmustine or PCV adjuvant chemotherapy. J
Clin Oncol. 1999; 17:3389-3395. [0100] 25. Fine H A, Dear K B,
Loeffler J S, Black P M, Canellos G P. Meta-analysis of radiation
therapy with and without adjuvant chemotherapy for malignant
gliomas in adults. Cancer. 1993; 71:2585-2597. [0101] 26. Mahaley M
S, Gillespie G Y. New therapeutic approaches to treatment of
malignant gliomas: chemotherapy and immunotherapy. Clin Neurosurg.
1983; 31:456-469. [0102] 27. Millot F, Delval O, Giraud C, et al.
High-dose chemotherapy with hematopoietic stem cell transplantation
in adults with bone marrow relapse of medulloblastoma: report of
two cases. Bone Marrow Transplant. 1999; 24:1347-1349. [0103] 28.
Kalifa C, Valteau D, Pizer B, Vassal G, Grill J, Hartmann O.
High-dose chemotherapy in childhood brain tumours. Childs Nerv
Syst. 1999; 15:498-505. [0104] 29. Finlay J L. The role of
high-dose chemotherapy and stem cell rescue in the treatment of
malignant brain tumors. Bone Marrow Transplant. 1996; 18 Suppl
3:S1-S5. [0105] 30. Brandes A A, Vastola F, Monfardini S.
Reoperation in recurrent high-grade gliomas: literature review of
prognostic factors and outcome. Am J Clin Oncol. 1999; 22:387-390.
[0106] 31. Miyagi K, Ingram M, Techy G B, Jacques D B, Freshwater D
B, Sheldon H. Immunohistochemical detection and correlation between
MHC antigen and cell-mediated immune system in recurrent glioma by
APAAP method. Neurol Med Chir (Tokyo). 1990; 30:649-655. [0107] 32.
Bauman G S, Sneed P K, Wara W M, et al. Reirradiation of primary
CNS tumors. Int Radiat Oncol Biol Phys. 1996; 36:433-441. [0108]
33. Fine H A. Novel biologic therapies for malignant gliomas.
Antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin.
1995; 13:827-846. [0109] 34. Brandes A A, Pasetto L M. New
therapeutic agents in the treatment of recurrent high-grade
gliomas. Forum (Genova). 2000; 10:121-131. [0110] 35. Pollack I F,
Okada H, Chambers W H. Exploitation of immune mechanisms in the
treatment of central nervous system cancer. Semin Pediatr Neurol.
2000; 7:131-143. [0111] 36. Black K L, Pikul B K. Gliomas--past,
present, and future. Clin Neurosurg. 1999; 45:160-163. [0112] 37.
Riva P, Franceschi G, Arista A, et al. Local application of
radiolabeled monoclonal antibodies in the treatment of high grade
malignant gliomas: a six-year clinical experience. Cancer. 1997;
80:2733-2742. [0113] 38. Liang B C, Weil M. Locoregional approaches
to therapy with gliomas as the paradigm. Curr Opin Oncol. 1998;
10:201-206. [0114] 39. Yu J S, Wei M X, Chiocca E A, Martuza R L,
Tepper R I. Treatment of glioma by engineered interleukin
4-secreting cells. Cancer Res. 1993; 53:3125-3128. [0115] 40. Alavi
J B, Eck S L. Gene therapy for malignant gliomas. Hematol Oncol
Clin North Am. 1998; 12:617-629. [0116] 41. Debinski W. Recombinant
cytotoxins specific for cancer cells. Ann N Y Acad. Sci. 1999;
886:297-299. [0117] 42. Debinski W, Gibo D M. Molecular expression
analysis of restrictive receptor for interleukin 13, a brain
tumor-associated cancer/testis antigen. Mol. Med. 2000; 6:440-449.
[0118] 43. Mintz A, Debinski W. Cancer genetics/epigenetics and the
X chromosome: possible new links for malignant glioma pathogenesis
and immune-based therapies. Crit. Rev Oncog. 2000; 11:77-95. [0119]
44. Joshi B H, Plautz G E, Puri R K. Interleukin-13 receptor alpha
chain: a novel tumor-associated transmembrane protein in primary
explants of human malignant gliomas. Cancer Res. 2000;
60:1168-1172. [0120] 45. Debinski W, Obiri N I, Powers S K, Pastan
I, Puri R K. Human glioma cells overexpress receptors for
interleukin 13 and are extremely sensitive to a novel chimeric
protein composed of interleukin 13 and pseudomonas exotoxin. Clin
Cancer Res. 1995; 1:1253-1258. [0121] 46. Debinski W, Gibo D M,
Hulet S W, Connor J R, Gillespie G Y. Receptor for interleukin 13
is a marker and therapeutic target for human high-grade gliomas.
Clin Cancer Res. 1999; 5:985-990. [0122] 47. Debinski W. An immune
regulatory cytokine receptor and glioblastoma multiforme: an
unexpected link. Crit. Rev Oncog. 1998; 9:255-268. [0123] 48.
Debinski W, Slagle B, Gibo D M, Powers S K, Gillespie G Y.
Expression of a restrictive receptor for interleukin 13 is
associated with glial transformation. J. Neurooncol. 2000;
48:103-111. [0124] 49. Debinski W, Miner R, Leland P, Obiri N I,
Puri R K. Receptor for interleukin (IL) 13 does not interact with
IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
J Biol. Chem. 1996; 271:22428-22433. [0125] 50. Murata T, Obiri N
I, Debinski W, Puri R K. Structure of IL-13 receptor: analysis of
subunit composition in cancer and immune cells. Biochem Biophys Res
Commun. 1997; 238:90-94. [0126] 51. Opal S M, DePalo V A.
Anti-inflammatory cytokines. Chest. 2000; 117:1162-1172. [0127] 52.
Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma
Immunol. 2000; 85:9-18. [0128] 53. Spellberg B, Edwards J E, Jr.
Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis.
2001; 32:76-102. [0129] 54. Liu H, Jacobs B S, Liu J, et al.
Interleukin-13 sensitivity and receptor phenotypes of human glial
cell lines: non-neoplastic glia and low-grade astrocytoma differ
from malignant glioma. Cancer Immunol Immunother. 2000; 49:319-324.
[0130] 55. Debinski W, Gibo D M, Obiri N I, Kealiher A, Puri R K.
Novel anti-brain tumor cytotoxins specific for cancer cells. Nat.
Biotechnol. 1998; 16:449-453. [0131] 56. Debinski W, Gibo D M, Puri
R K. Novel way to increase targeting specificity to a human
glioblastoma-associated receptor for interleukin 13. Int J. Cancer.
1998; 76:547-551. [0132] 57. Debinski W, Thompson J P. Retargeting
interleukin 13 for radioimmunodetection and radioimmunotherapy of
human high-grade gliomas. Clin Cancer Res. 1999; 5:3143s-3147s.
[0133] 58. Thompson J P, Debinski W. Mutants of interleukin 13 with
altered reactivity toward interleukin 13 receptors. J Biol. Chem.
1999; 274:29944-29950. [0134] 59. Brooks W H, Netsky M G, Levine J
E. Immunity and tumors of the nervous system. Surg Neurol. 1975;
3:184-186. [0135] 60. Bullard D E, Gillespie G Y, Mahaley M S,
Bigner D D. Immunobiology of human gliomas. Semin Oncol. 1986;
13:94-109. [0136] 61. Coakham H B. Immunology of human brain
tumors. Eur J Cancer Clin Oncol. 1984; 20:145-149. [0137] 62.
Holladay F P, Heitz T, Wood G W. Antitumor activity against
established intracerebral gliomas exhibited by cytotoxic T
lymphocytes, but not by lymphokine-activated killer cells. J.
Neurosurg. 1992; 77:757-762. [0138] 63. Holladay F P, Heitz T, Chen
Y L, Chiga M, Wood G W. Successful treatment of a malignant rat
glioma with cytotoxic T lymphocytes. Neurosurgery. 1992;
31:528-533. [0139] 64. Kruse C A, Lillehei K O, Mitchell D H,
Kleinschmidt-DeMasters B, Bellgrau D. Analysis of interleukin 2 and
various effector cell populations in adoptive immunotherapy of 9L
rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor
take. Proc Natl Acad Sci USA. 1990; 87:9577-9581. [0140] 65.
Miyatake S, Nishihara K, Kikuchi H, et al. Efficient tumor
suppression by glioma-specific murine cytotoxic T lymphocytes
transfected with interferon-gamma gene. J Natl Cancer Inst. 1990;
82:217-220. [0141] 66. Plautz G E, Touhalisky J E, Shu S. Treatment
of murine gliomas by adoptive transfer of ex vivo activated
tumor-draining lymph node cells. Cell Immunol. 1997; 178:101-107.
[0142] 67. Saris S C, Spiess P, Lieberman D M, Lin S, Walbridge S,
Oldfield E H. Treatment of murine primary brain tumors with
systemic interleukin-2 and tumor-infiltrating lymphocytes. J.
Neurosurg. 1992; 76:513-519. [0143] 68. Tzeng J J, Barth R F,
Clendenon N R, Gordon W A. Adoptive immunotherapy of a rat glioma
using lymphokine-activated killer cells and interleukin 2. Cancer
Res. 1990; 50:4338-4343. [0144] 69. Yamasaki T, Kikuchi H. An
experimental approach to specific adoptive immunotherapy for
malignant brain tumors. Nippon Geka Hokan. 1989; 58:485-492. [0145]
70. Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka
M. Specific adoptive immunotherapy with tumor-specific cytotoxic
T-lymphocyte clone for murine malignant gliomas. Cancer Res. 1984;
44:1776-1783. [0146] 71. Yamasaki T, Handa H, Yamashita J, Watanabe
Y, Namba Y, Hanaoka M. Specific adoptive immunotherapy of malignant
glioma with long-term cytotoxic T lymphocyte line expanded in
T-cell growth factor. Experimental study and future prospects.
Neurosurg Rev. 1984; 7:37-54. [0147] 72. Kikuchi K, Neuwelt E A.
Presence of immunosuppressive factors in brain-tumor cyst fluid. J.
Neurosurg. 1983; 59:790-799. [0148] 73. Yamanaka R, Tanaka R,
Yoshida S, Saitoh T, Fujita K, Naganuma H. Suppression of TGF-beta1
in human gliomas by retroviral gene transfection enhances
susceptibility to LAK cells. J. Neurooncol. 1999; 43:27-34. [0149]
74. Kuppner M C, Hamou M F, Bodmer S, Fontana A, de Tribolet N. The
glioblastoma-derived T-cell suppressor factor/transforming growth
factor beta 2 inhibits the generation of lymphokine-activated
killer (LAK) cells. Int J. Cancer. 1988; 42:562-567. [0150] 75.
Hayes R L. The cellular immunotherapy of primary brain tumors. Rev
Neurol (Paris). 1992; 148:454-466. [0151] 76. Ingram M, Buckwalter
J G, Jacques D B, et al. Immunotherapy for recurrent malignant
glioma: an interim report on survival. Neurol Res. 1990;
12:265-273. [0152] 77. Jaeckle K A. Immunotherapy of malignant
gliomas. Semin Oncol. 1994; 21:249-259. [0153] 78. Kruse C A,
Cepeda L, Owens B, Johnson S D, Stears J, Lillehei K O. Treatment
of recurrent glioma with intracavitary alloreactive cytotoxic T
lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997;
45:77-87. [0154] 79. Merchant R E, Baldwin N G, Rice C D, Bear H D.
Adoptive immunotherapy of malignant glioma using tumor-sensitized T
lymphocytes. Neurol Res. 1997; 19:145-152. [0155] 80. Nakagawa K,
Kamezaki T, Shibata Y, Tsunoda T, Meguro K, Nose T. Effect of
lymphokine-activated killer cells with or without radiation therapy
against malignant brain tumors. Neurol Med Chir (Tokyo). 1995;
35:22-27. [0156] 81. Plautz G E, Barnett G H, Miller D W, et al.
Systemic T cell adoptive immunotherapy of malignant gliomas. J.
Neurosurg. 1998; 89:42-51. [0157] 82. Sankhla S K, Nadkarni J S,
Bhagwati S N. Adoptive immunotherapy using lymphokine-activated
killer (LAK) cells and interleukin-2 for recurrent malignant
primary brain tumors. J. Neurooncol. 1996; 27:133-140. [0158] 83.
Sawamura Y, de Tribolet N. Immunotherapy of brain tumors. J
Neurosurg Sci. 1990; 34:265-278. [0159] 84. Thomas C, Schober R,
Lenard H G, Lumenta C B, Jacques D B, Wechsler W. Immunotherapy
with stimulated autologous lymphocytes in a case of a juvenile
anaplastic glioma. Neuropediatrics. 1992; 23:123-125. [0160] 85.
Tsurushima H, Liu S Q, Tuboi K, et al. Reduction of end-stage
malignant glioma by injection with autologous cytotoxic T
lymphocytes. Jpn J Cancer Res. 1999; 90:536-545. [0161] 86. Barba
D, Saris S C, Holder C, Rosenberg S A, Oldfield E H. Intratumoral
LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg.
1989; 70:175-182. [0162] 87. Hayes R L, Koslow M, Hiesiger E M, et
al. Improved long term survival after intracavitary interleukin-2
and lymphokine-activated killer cells for adults with recurrent
malignant glioma. Cancer. 1995; 76:840-852.
[0163] 88. Ingram M, Jacques S, Freshwater D B, Techy G B, Shelden
C H, Helsper J T. Salvage immunotherapy of malignant glioma. Arch
Surg. 1987; 122:1483-1486. [0164] 89. Jacobs S K, Wilson D J,
Kornblith P L, Grimm E A. Interleukin-2 or autologous
lymphokine-activated killer cell treatment of malignant glioma:
phase I trial. Cancer Res. 1986; 46:2101-2104. [0165] 90. Jeffes E
W, III, Beamer Y B, Jacques S, et al. Therapy of recurrent
high-grade gliomas with surgery, autologous mitogen-activated
IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II.
Correlation of survival with MAK cell tumor necrosis factor
production in vitro. Lymphokine Cytokine Res. 1991; 10:89-94.
[0166] 91. Merchant R E, McVicar D W, Merchant L H, Young H F.
Treatment of recurrent malignant glioma by repeated intracerebral
injections of human recombinant interleukin-2 alone or in
combination with systemic interferon-alpha. Results of a phase I
clinical trial. J. Neurooncol. 1992; 12:75-83. [0167] 92. Yoshida
S, Takai N, Saito T, Tanaka R. Adoptive immunotherapy in patients
with malignant glioma. Gan To Kagaku Ryoho. 1987; 14:1930-1932.
[0168] 93. Davico B L, De Monte L B, Spagnoli G C, et al.
Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an
immunotherapeutic agent for human glioma. Int J. Cancer. 1995;
61:509-515. [0169] 94. Jung G, Brandl M, Eisner W, et al. Local
immunotherapy of glioma patients with a combination of 2 bispecific
antibody fragments and resting autologous lymphocytes: evidence for
in situ t-cell activation and therapeutic efficacy. Int J.Cancer.
2001; 91:225-230. [0170] 95. Pfosser A, Brandl M, Salih H,
Grosse-Hovest L, Jung G. Role of target antigen in
bispecific-antibody-mediated killing of human glioblastoma cells: a
pre-clinical study. Int J. Cancer. 1999; 80:612-616. [0171] 96.
Yoshida J, Takaoka T, Mizuno M, Momota H, Okada H. Cytolysis of
malignant glioma cells by lymphokine-activated killer cells
combined with anti-CD3/antiglioma bifunctional antibody and tumor
necrosis factor-alpha. J Surg Oncol. 1996; 62:177-182. [0172] 97.
Imaizumi T, Kuramoto T, Matsunaga K, et al. Expression of the
tumor-rejection antigen SART1 in brain tumors. Int J. Cancer. 1999;
83:760-764. [0173] 98. Eshhar Z, Waks T, Gross G, Schindler D G.
Specific activation and targeting of cytotoxic lymphocytes through
chimeric single chains consisting of antibody-binding domains and
the gamma or zeta subunits of the immunoglobulin and T-cell
receptors. Proc Natl Acad Sci USA. 1993; 90:720-724. [0174] 99.
Haynes N M, Snook M B, Trapani J A, et al. Redirecting mouse CTL
against colon carcinoma: superior signaling efficacy of
single-chain variable domain chimeras containing TCR-zeta vs Fc
epsilon RI-gamma. J. Immunol. 2001; 166:182-187. [0175] 100.
Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric
receptor that mediates CD3-zeta-independent T-cell activation
against Hodgkin's lymphoma cells in the presence of soluble CD30.
Cancer Res. 1998; 58:1116-1119. [0176] 101. Hombach A, Schneider C,
Sent D, et al. An entirely humanized CD3 zeta-chain signaling
receptor that directs peripheral blood t cells to specific lysis of
carcinoembryonic antigen-positive tumor cells. Int J. Cancer. 2000;
88:115-120. [0177] 102. Hombach A, Sircar R, Heuser C, et al.
Chimeric anti-TAG72 receptors with immunoglobulin constant Fc
domains and gamma or zeta signalling chains. Int J Mol. Med. 1998;
2:99-103. [0178] 103. Moritz D, Wels W, Mattern J, Groner B.
Cytotoxic T lymphocytes with a grafted recognition specificity for
ERBB2-expressing tumor cells. Proc Natl Acad Sci USA. 1994;
91:4318-4322. [0179] 104. Weijtens M E, Willemsen R A, Valerio D,
Stam K, Bolhuis R L. Single chain Ig/gamma gene-redirected human T
lymphocytes produce cytokines, specifically lyse tumor cells, and
recycle lytic capacity. J. Immunol. 1996; 157:836-843. [0180] 105.
Altenschmidt U, Klundt E, Groner B. Adoptive transfer of in
vitro-targeted, activated T lymphocytes results in total tumor
regression. J. Immunol. 1997; 159:5509-5515. [0181] 106. Jensen M,
Tan G, Forman S, Wu A M, Raubitschek A. CD20 is a molecular target
for scFvFc:zeta receptor redirected T cells: implications for
cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow
Transplant. 1998; 4:75-83. [0182] 107. Jensen M C, Clarke P, Tan G,
et al. Human T lymphocyte genetic modification with naked DNA. Mol.
Ther. 2000; 1:49-55. [0183] 108. Minty A, Chalon P, Derocq J M, et
al. Interleukin-13 is a new human lymphokine regulating
inflammatory and immune responses. Nature. 1993; 362:248-250.
[0184] 109. Boon T, Cerottini J C, Van den E B, van der B P, Van
Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev
Immunol. 1994; 12:337-365. [0185] 110. Castelli C, Rivoltini L,
Andreola G, Carrabba M, Renkvist N. Parmiani G. T-cell recognition
of melanoma-associated antigens. J Cell Physiol. 2000; 182:323-331.
[0186] 111. Chi D D, Merchant R E, R and R, et al. Molecular
detection of tumor-associated antigens shared by human cutaneous
melanomas and gliomas. Am J. Pathol. 1997; 150:2143-2152. [0187]
112. Boon T, Coulie P, Marchand M, Weynants P, Wolfel T, Brichard
V. Genes coding for tumor rejection antigens: perspectives for
specific immunotherapy. Important Adv Oncol. 1994;53-69. [0188]
113. Cebon J, MacGregor D, Scott A, DeBoer R. Immunotherapy of
melanoma: targeting defined antigens. Australas J. Dermatol. 1997;
38 Suppl 1:S66-S72. [0189] 114. Greenberg P D, Riddell S R.
Tumor-specific T-cell immunity: ready for prime time? J Natl Cancer
Inst. 1992; 84:1059-1061. [0190] 115. Cohen J L, Saron M F, Boyer
O, et al. Preservation of graft-versus-infection effects after
suicide gene therapy for prevention of graft-versus-host disease.
Hum Gene Ther. 2000; 11:2473-2481. [0191] 116. Drobyski W R, Morse
H C, III, Burns W H, Casper J T, Sandford G. Protection from lethal
murine graft-versus-host disease without compromise of
alloengraftment using transgenic donor T cells expressing a
thymidine kinase suicide gene. Blood. 2001; 97:2506-2513. [0192]
117. Link C J, Jr., Traynor A, Seregina T, Burt R K. Adoptive
immunotherapy for leukemia: donor lymphocytes transduced with the
herpes simplex thymidine kinase gene. Cancer Treat Res. 1999;
101:369-375. [0193] 118. Spencer D M. Developments in suicide genes
for preclinical and clinical applications. Curr Opin Mol. Ther.
2000; 2:433-440.
Sequence CWU 1
1
181102DNAHomo sapiensmisc_feature(4)..(9)EcoRI restriction site
1tatgaattca tggcgctttt gttgaccacg gtcattgctc tcacttgcct tggcggcttt
60gcctccccag gccctgtgcc tccctctaca gccctcaggt ac 1022101DNAHomo
sapiens 2gttgatgctc cataccatgc tgccattgca gagcggagcc ttctggttct
gggtgatgtt 60gaccagctcc tcaatgaggt acctgagggc tgtagaggga g
1013100DNAHomo sapiens 3ctctgggtct tctcgatggc actgcagcct gacacgttga
tcagggattc cagggctgca 60cagtacatgc cagctgtcag gttgatgctc cataccatgc
1004100DNAHomo sapiens 4cctcgatttt ggtgtctcgg acatgcaagc tggaaaactg
cccagctgag accttgtgcg 60ggcagaatcc gctcagcatc ctctgggtct tctcgatggc
100596DNAHomo sapiensmisc_feature(3)..(8)BamHI restriction site
5tcggatcctc agttgaaccg tccctcgcga aaaagtttct ttaaatgtaa gagcaggtcc
60tttacaaact gggccacctc gattttggtg tctcgg 96639DNAHomo sapiens
6caacctgaca gctggcatgt actgtgcagc cctggaatc 39739DNAHomo sapiens
7gattccaggg ctgcacagta catgccagct gtcaggttg 39843DNAHomo
sapiensmisc_feature(4)..(9)XbaI restriction site 8atctctagag
ccgccaccat gcttctcctg gtgacaagcc ttc 43934DNAHomo sapiens
9gagggaggca cagggcctgg gatcaggagg aatg 341034DNAHomo sapiens
10cattcctcct gatcccaggc cctgtgcctc cctc 341135DNAHomo sapiens
11gggaccatat ttggactcgt tgaaccgtcc ctcgc 351235DNAHomo sapiens
12gcgagggacg gttcaacgag tccaaatatg gtccc 351326DNAHomo
sapiensmisc_feature(3)..(10)NotI restriction site 13atgcggccgc
tcagcgaggg ggcagg 26146783DNAArtificial Sequenceplasmid DNA vector
incorporating human, simian virus 40, E. coli,cytomegalovirus and
bovine sequences 14tcgaaggatc tgcgatcgct ccggtgcccg tcagtgggca
gagcgcacat cgcccacagt 60ccccgagaag ttggggggag gggtcggcaa ttgaaccggt
gcctagagaa ggtggcgcgg 120ggtaaactgg gaaagtgatg tcgtgtactg
gctccgcctt tttcccgagg gtgggggaga 180accgtatata agtgcagtag
tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag 240aacacagctg
aagcttcgag gggctcgcat ctctccttca cgcgcccgcc gccctacctg
300aggccgccat ccacgccggt tgagtcgcgt tctgccgcct cccgcctgtg
gtgcctcctg 360aactgcgtcc gccgtctagg taagtttaaa gctcaggtcg
agaccgggcc tttgtccggc 420gctcccttgg agcctaccta gactcagccg
gctctccacg ctttgcctga ccctgcttgc 480tcaactctac gtctttgttt
cgttttctgt tctgcgccgt tacagatcca agctgtgacc 540ggcgcctacg
taagtgatat ctactagatt tatcaaaaag agtgttgact tgtgagcgct
600cacaattgat acggattcat cgagagggac acgtcgacta ctaaccttct
tctctttcct 660acagctgaga tcaccctaga gccgccacca tgcttctcct
ggtgacaagc cttctgctct 720gtgagttacc acacccagca ttcctcctga
tcccaggccc tgtgcctccc tctacagccc 780tcaggtacct cattgaggag
ctggtcaaca tcacccagaa ccagaaggct ccgctctgca 840atggcagcat
ggtatggagc atcaacctga cagctggcat gtactgtgca gccctggaat
900ccctgatcaa cgtgtcaggc tgcagtgcca tcgagaagac ccagaggatg
ctgagcggat 960tctgcccgca caaggtctca gctgggcagt tttccagctt
gcatgtccga gacaccaaaa 1020tcgaggtggc ccagtttgta aaggacctgc
tcttacattt aaagaaactt tttcgcgagg 1080gacggttcaa cgagtccaaa
tatggtcccc catgcccacc atgcccagca cctgagttcc 1140tggggggacc
atcagtcttc ctgttccccc caaaacccaa ggacactctc atgatctccc
1200ggacccctga ggtcacgtgc gtggtggtgg acgtgagcca ggaagacccc
gaggtccagt 1260tcaactggta cgtggatggc gtggaggtgc ataatgccaa
gacaaagccg cgggaggagc 1320agttcaacag cacgtaccgt gtggtcagcg
tcctcaccgt cctgcaccag gactggctga 1380acggcaagga gtacaagtgc
aaggtctcca acaaaggcct cccgtcctcc atcgagaaaa 1440ccatctccaa
agccaaaggg cagccccgag agccacaggt gtacaccctg cccccatccc
1500aggaggagat gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc
ttctacccca 1560gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga
gaacaactac aagaccacgc 1620ctcccgtgct ggactccgac ggctccttct
tcctctacag caggctaacc gtggacaaga 1680gcaggtggca ggaggggaat
gtcttctcat gctccgtgat gcatgaggct ctgcacaacc 1740actacacaca
gaagagcctc tccctgtccc taggtaaaat ggccctgatt gtgctggggg
1800gcgtcgccgg cctcctgctt ttcattgggc taggcatctt cttcagagtg
aagttcagca 1860ggagcgcaga cgcccccgcg taccagcagg gccagaacca
gctctataac gagctcaatc 1920taggacgaag agaggagtac gatgttttgg
acaagagacg tggccgggac cctgagatgg 1980ggggaaagcc gagaaggaag
aaccctcagg aaggcctgta caatgaactg cagaaagata 2040agatggcgga
ggcctacagt gagattggga tgaaaggcga gcgccggagg ggcaaggggc
2100acgatggcct ttaccagggt ctcagtacag ccaccaagga cacctacgac
gcccttcaca 2160tgcaggccct gccccctcgc tgagcggccg gcgaaggagg
cctagatcta tcgattgtac 2220agctagctcg acatgataag atacattgat
gagtttggac aaaccacaac tagaatgcag 2280tgaaaaaaat gctttatttg
tgaaatttgt gatgctattg ctttatttgt gaaatttgtg 2340atgctattgc
tttatttgta accattataa gctgcaataa acaagttaac aacaacaatt
2400gcattcattt tatgtttcag gttcaggggg aggtgtggga ggttttttaa
agcaagtaaa 2460acctctacaa atgtggtaga tccatttaaa tgttagcgaa
gaacatgtga gcaaaaggcc 2520agcaaaaggc caggaaccgt aaaaaggccg
cgttgctggc gtttttccat aggctccgcc 2580cccctgacga gcatcacaaa
aatcgacgct caagtcagag gtggcgaaac ccgacaggac 2640tataaagata
ccaggcgttt ccccctggaa gctccctcgt gcgctctcct gttccgaccc
2700tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg
ctttctcaat 2760gctcacgctg taggtatctc agttcggtgt aggtcgttcg
ctccaagctg ggctgtgtgc 2820acgaaccccc cgttcagccc gaccgctgcg
ccttatccgg taactatcgt cttgagtcca 2880acccggtaag acacgactta
tcgccactgg cagcagccac tggtaacagg attagcagag 2940cgaggtatgt
aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta
3000gaagaacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga
aaaagagttg 3060gtagctcttg atccggcaaa caaaccaccg ctggtagcgg
tggttttttt gtttgcaagc 3120agcagattac gcgcagaaaa aaaggatctc
aagaagatcc tttgatcttt tctacggggt 3180ctgacgctca gtggaacgaa
aactcacgtt aagggatttt ggtcatggct agttaattaa 3240gctgcaataa
acaatcatta ttttcattgg atctgtgtgt tggttttttg tgtgggcttg
3300ggggaggggg aggccagaat gactccaaga gctacaggaa ggcaggtcag
agaccccact 3360ggacaaacag tggctggact ctgcaccata acacacaatc
aacaggggag tgagctggat 3420cgagctagag tccgttacat aacttacggt
aaatggcccg cctggctgac cgcccaacga 3480cccccgccca ttgacgtcaa
taatgacgta tgttcccata gtaacgccaa tagggacttt 3540ccattgacgt
caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt
3600gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc
ccgcctggca 3660ttatgcccag tacatgacct tatgggactt tcctacttgg
cagtacatct acgtattagt 3720catcgctatt accatggtga tgcggttttg
gcagtacatc aatgggcgtg gatagcggtt 3780tgactcacgg ggatttccaa
gtctccaccc cattgacgtc aatgggagtt tgttttggca 3840ccaaaatcaa
cgggactttc caaaatgtcg taacaactcc gccccattga cgcaaatggg
3900cggtaggcgt gtacggtggg aggtctatat aagcagagct cgtttagtga
accgtcagat 3960cgcctggaga cgccatccac gctgttttga cctccataga
agacaccggg accgatccag 4020cctccgcggc cgggaacggt gcattggaac
gcggattccc cgtgccaaga gtgacgtaag 4080taccgcctat agagtctata
ggcccaccta gttgtgaccg gcgcctagtg ttgacaatta 4140atcatcggca
tagtatatcg gcatagtata atacgactca ctataggagg gccaccatgt
4200cgactactaa ccttcttctc tttcctacag ctgagatcac cggtaggagg
gccatcatga 4260aaaagcctga actcaccgcg acgtctgtcg cgaagtttct
gatcgaaaag ttcgacagcg 4320tctccgacct gatgcagctc tcggagggcg
aagaatctcg tgctttcagc ttcgatgtag 4380gagggcgtgg atatgtcctg
cgggtaaata gctgcgccga tggtttctac aaagatcgtt 4440atgtttatcg
gcactttgca tcggccgcgc tcccgattcc ggaagtgctt gacattgggg
4500aattcagcga gagcctgacc tattgcatct cccgccgtgc acagggtgtc
acgttgcaag 4560acctgcctga aaccgaactg cccgctgttc tgcaacccgt
cgcggagctc atggatgcga 4620tcgctgcggc cgatcttagc cagacgagcg
ggttcggccc attcggaccg caaggaatcg 4680gtcaatacac tacatggcgt
gatttcatat gcgcgattgc tgatccccat gtgtatcact 4740ggcaaactgt
gatggacgac accgtcagtg cgtccgtcgc gcaggctctc gatgagctga
4800tgctttgggc cgaggactgc cccgaagtcc ggcacctcgt gcacgcggat
ttcggctcca 4860acaatgtcct gacggacaat ggccgcataa cagcggtcat
tgactggagc gaggcgatgt 4920tcggggattc ccaatacgag gtcgccaaca
tcttcttctg gaggccgtgg ttggcttgta 4980tggagcagca gacgcgctac
ttcgagcgga ggcatccgga gcttgcagga tcgccgcggc 5040tccgggcgta
tatgctccgc attggtcttg accaactcta tcagagcttg gttgacggca
5100atttcgatga tgcagcttgg gcgcagggtc gatgcgacgc aatcgtccga
tccggagccg 5160ggactgtcgg gcgtacacaa atcgcccgca gaagcgcggc
cgtctggacc gatggctgtg 5220tagaagtcgc gtctgcgttc gaccaggctg
cgcgttctcg cggccatagc aaccgacgta 5280cggcgttgcg ccctcgccgg
cagcaagaag ccacggaagt ccgcccggag cagaaaatgc 5340ccacgctact
gcgggtttat atagacggtc cccacgggat ggggaaaacc accaccacgc
5400aactgctggt ggccctgggt tcgcgcgacg atatcgtcta cgtacccgag
ccgatgactt 5460actggcgggt gctgggggct tccgagacaa tcgcgaacat
ctacaccaca caacaccgcc 5520tcgaccaggg tgagatatcg gccggggacg
cggcggtggt aatgacaagc gcccagataa 5580caatgggcat gccttatgcc
gtgaccgacg ccgttctggc tcctcatatc gggggggagg 5640ctgggagctc
acatgccccg cccccggccc tcaccctcat cttcgaccgc catcccatcg
5700ccgccctcct gtgctacccg gccgcgcggt accttatggg cagcatgacc
ccccaggccg 5760tgctggcgtt cgtggccctc atcccgccga ccttgcccgg
caccaacatc gtgcttgggg 5820cccttccgga ggacagacac atcgaccgcc
tggccaaacg ccagcgcccc ggcgagcggc 5880tggacctggc tatgctggct
gcgattcgcc gcgtttacgg gctacttgcc aatacggtgc 5940ggtatctgca
gtgcggcggg tcgtggcggg aggactgggg acagctttcg gggacggccg
6000tgccgcccca gggtgccgag ccccagagca acgcgggccc acgaccccat
atcggggaca 6060cgttatttac cctgtttcgg gcccccgagt tgctggcccc
caacggcgac ctgtataacg 6120tgtttgcctg ggccttggac gtcttggcca
aacgcctccg ttccatgcac gtctttatcc 6180tggattacga ccaatcgccc
gccggctgcc gggacgccct gctgcaactt acctccggga 6240tggtccagac
ccacgtcacc acccccggct ccataccgac gatatgcgac ctggcgcgca
6300cgtttgcccg ggagatgggg gaggctaact gagtcgagaa ttcgctagag
ggccctattc 6360tatagtgtca cctaaatgct agagctcgct gatcagcctc
gactgtgcct tctagttgcc 6420agccatctgt tgtttgcccc tcccccgtgc
cttccttgac cctggaaggt gccactccca 6480ctgtcctttc ctaataaaat
gaggaaattg catcgcattg tctgagtagg tgtcattcta 6540ttctgggggg
tggggtgggg caggacagca agggggagga ttgggaagac aatagcaggc
6600atgcgcaggg cccaattgct cgagcggccg caataaaata tctttatttt
cattacatct 6660gtgtgttggt tttttgtgtg aatcgtaact aacatacgct
ctccatcaaa acaaaacgaa 6720acaaaacaaa ctagcaaaat aggctgtccc
cagtgcaagt gcaggtgcca gaacatttct 6780cta 6783151491DNAHomo sapiens
15atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg
60atcccaggcc ctgtgcctcc ctctacagcc ctcaggtacc tcattgagga gctggtcaac
120atcacccaga accagaaggc tccgctctgc aatggcagca tggtatggag
catcaacctg 180acagctggca tgtactgtgc agccctggaa tccctgatca
acgtgtcagg ctgcagtgcc 240atcgagaaga cccagaggat gctgagcgga
ttctgcccgc acaaggtctc agctgggcag 300ttttccagct tgcatgtccg
agacaccaaa atcgaggtgg cccagtttgt aaaggacctg 360ctcttacatt
taaagaaact ttttcgcgag ggacggttca acgagtccaa atatggtccc
420ccatgcccac catgcccagc acctgagttc ctggggggac catcagtctt
cctgttcccc 480ccaaaaccca aggacactct catgatctcc cggacccctg
aggtcacgtg cgtggtggtg 540gacgtgagcc aggaagaccc cgaggtccag
ttcaactggt acgtggatgg cgtggaggtg 600cataatgcca agacaaagcc
gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 660gtcctcaccg
tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc
720aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg
gcagccccga 780gagccacagg tgtacaccct gcccccatcc caggaggaga
tgaccaagaa ccaggtcagc 840ctgacctgcc tggtcaaagg cttctacccc
agcgacatcg ccgtggagtg ggagagcaat 900gggcagccgg agaacaacta
caagaccacg cctcccgtgc tggactccga cggctccttc 960ttcctctaca
gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca
1020tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct
ctccctgtct 1080ctgggtaaaa tggccctgat tgtgctgggg ggcgtcgccg
gcctcctgct tttcattggg 1140ctaggcatct tcttcagagt gaagttcagc
aggagcgcag acgcccccgc gtaccagcag 1200ggccagaacc agctctataa
cgagctcaat ctaggacgaa gagaggagta cgatgttttg 1260gacaagagac
gtggccggga ccctgagatg gggggaaagc cgagaaggaa gaaccctcag
1320gaaggcctgt acaatgaact gcagaaagat aagatggcgg aggcctacag
tgagattggg 1380atgaaaggcg agcgccggag gggcaagggg cacgatggcc
tttaccaggg tctcagtaca 1440gccaccaagg acacctacga cgcccttcac
atgcaggccc tgccccctcg c 1491166783DNAArtificial Sequenceplasmid DNA
vector incorporating human, simian virus 40, E. coli,
cytomegalovirus and bovine sequences 16tagagaaatg ttctggcacc
tgcacttgca ctggggacag cctattttgc tagtttgttt 60tgtttcgttt tgttttgatg
gagagcgtat gttagttacg attcacacaa aaaaccaaca 120cacagatgta
atgaaaataa agatatttta ttgcggccgc tcgagcaatt gggccctgcg
180catgcctgct attgtcttcc caatcctccc ccttgctgtc ctgccccacc
ccacccccca 240gaatagaatg acacctactc agacaatgcg atgcaatttc
ctcattttat taggaaagga 300cagtgggagt ggcaccttcc agggtcaagg
aaggcacggg ggaggggcaa acaacagatg 360gctggcaact agaaggcaca
gtcgaggctg atcagcgagc tctagcattt aggtgacact 420atagaatagg
gccctctagc gaattctcga ctcagttagc ctcccccatc tcccgggcaa
480acgtgcgcgc caggtcgcat atcgtcggta tggagccggg ggtggtgacg
tgggtctgga 540ccatcccgga ggtaagttgc agcagggcgt cccggcagcc
ggcgggcgat tggtcgtaat 600ccaggataaa gacgtgcatg gaacggaggc
gtttggccaa gacgtccaag gcccaggcaa 660acacgttata caggtcgccg
ttgggggcca gcaactcggg ggcccgaaac agggtaaata 720acgtgtcccc
gatatggggt cgtgggcccg cgttgctctg gggctcggca ccctggggcg
780gcacggccgt ccccgaaagc tgtccccagt cctcccgcca cgacccgccg
cactgcagat 840accgcaccgt attggcaagt agcccgtaaa cgcggcgaat
cgcagccagc atagccaggt 900ccagccgctc gccggggcgc tggcgtttgg
ccaggcggtc gatgtgtctg tcctccggaa 960gggccccaag cacgatgttg
gtgccgggca aggtcggcgg gatgagggcc acgaacgcca 1020gcacggcctg
gggggtcatg ctgcccataa ggtaccgcgc ggccgggtag cacaggaggg
1080cggcgatggg atggcggtcg aagatgaggg tgagggccgg gggcggggca
tgtgagctcc 1140cagcctcccc cccgatatga ggagccagaa cggcgtcggt
cacggcataa ggcatgccca 1200ttgttatctg ggcgcttgtc attaccaccg
ccgcgtcccc ggccgatatc tcaccctggt 1260cgaggcggtg ttgtgtggtg
tagatgttcg cgattgtctc ggaagccccc agcacccgcc 1320agtaagtcat
cggctcgggt acgtagacga tatcgtcgcg cgaacccagg gccaccagca
1380gttgcgtggt ggtggttttc cccatcccgt ggggaccgtc tatataaacc
cgcagtagcg 1440tgggcatttt ctgctccggg cggacttccg tggcttcttg
ctgccggcga gggcgcaacg 1500ccgtacgtcg gttgctatgg ccgcgagaac
gcgcagcctg gtcgaacgca gacgcgactt 1560ctacacagcc atcggtccag
acggccgcgc ttctgcgggc gatttgtgta cgcccgacag 1620tcccggctcc
ggatcggacg attgcgtcgc atcgaccctg cgcccaagct gcatcatcga
1680aattgccgtc aaccaagctc tgatagagtt ggtcaagacc aatgcggagc
atatacgccc 1740ggagccgcgg cgatcctgca agctccggat gcctccgctc
gaagtagcgc gtctgctgct 1800ccatacaagc caaccacggc ctccagaaga
agatgttggc gacctcgtat tgggaatccc 1860cgaacatcgc ctcgctccag
tcaatgaccg ctgttatgcg gccattgtcc gtcaggacat 1920tgttggagcc
gaaatccgcg tgcacgaggt gccggacttc ggggcagtcc tcggcccaaa
1980gcatcagctc atcgagagcc tgcgcgacgg acgcactgac ggtgtcgtcc
atcacagttt 2040gccagtgata cacatgggga tcagcaatcg cgcatatgaa
atcacgccat gtagtgtatt 2100gaccgattcc ttgcggtccg aatgggccga
acccgctcgt ctggctaaga tcggccgcag 2160cgatcgcatc catgagctcc
gcgacgggtt gcagaacagc gggcagttcg gtttcaggca 2220ggtcttgcaa
cgtgacaccc tgtgcacggc gggagatgca ataggtcagg ctctcgctga
2280attccccaat gtcaagcact tccggaatcg ggagcgcggc cgatgcaaag
tgccgataaa 2340cataacgatc tttgtagaaa ccatcggcgc agctatttac
ccgcaggaca tatccacgcc 2400ctcctacatc gaagctgaaa gcacgagatt
cttcgccctc cgagagctgc atcaggtcgg 2460agacgctgtc gaacttttcg
atcagaaact tcgcgacaga cgtcgcggtg agttcaggct 2520ttttcatgat
ggccctccta ccggtgatct cagctgtagg aaagagaaga aggttagtag
2580tcgacatggt ggccctccta tagtgagtcg tattatacta tgccgatata
ctatgccgat 2640gattaattgt caacactagg cgccggtcac aactaggtgg
gcctatagac tctataggcg 2700gtacttacgt cactcttggc acggggaatc
cgcgttccaa tgcaccgttc ccggccgcgg 2760aggctggatc ggtcccggtg
tcttctatgg aggtcaaaac agcgtggatg gcgtctccag 2820gcgatctgac
ggttcactaa acgagctctg cttatataga cctcccaccg tacacgccta
2880ccgcccattt gcgtcaatgg ggcggagttg ttacgacatt ttggaaagtc
ccgttgattt 2940tggtgccaaa acaaactccc attgacgtca atggggtgga
gacttggaaa tccccgtgag 3000tcaaaccgct atccacgccc attgatgtac
tgccaaaacc gcatcaccat ggtaatagcg 3060atgactaata cgtagatgta
ctgccaagta ggaaagtccc ataaggtcat gtactgggca 3120taatgccagg
cgggccattt accgtcattg acgtcaatag ggggcgtact tggcatatga
3180tacacttgat gtactgccaa gtgggcagtt taccgtaaat actccaccca
ttgacgtcaa 3240tggaaagtcc ctattggcgt tactatggga acatacgtca
ttattgacgt caatgggcgg 3300gggtcgttgg gcggtcagcc aggcgggcca
tttaccgtaa gttatgtaac ggactctagc 3360tcgatccagc tcactcccct
gttgattgtg tgttatggtg cagagtccag ccactgtttg 3420tccagtgggg
tctctgacct gccttcctgt agctcttgga gtcattctgg cctccccctc
3480ccccaagccc acacaaaaaa ccaacacaca gatccaatga aaataatgat
tgtttattgc 3540agcttaatta actagccatg accaaaatcc cttaacgtga
gttttcgttc cactgagcgt 3600cagaccccgt agaaaagatc aaaggatctt
cttgagatcc tttttttctg cgcgtaatct 3660gctgcttgca aacaaaaaaa
ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 3720taccaactct
ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgttc
3780ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg
cctacatacc 3840tcgctctgct aatcctgtta ccagtggctg ctgccagtgg
cgataagtcg tgtcttaccg 3900ggttggactc aagacgatag ttaccggata
aggcgcagcg gtcgggctga acggggggtt 3960cgtgcacaca gcccagcttg
gagcgaacga cctacaccga actgagatac ctacagcgtg 4020agcattgaga
aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg
4080gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc
tggtatcttt 4140atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg
atttttgtga tgctcgtcag 4200gggggcggag cctatggaaa aacgccagca
acgcggcctt tttacggttc ctggcctttt 4260gctggccttt tgctcacatg
ttcttcgcta acatttaaat ggatctacca catttgtaga 4320ggttttactt
gctttaaaaa acctcccaca cctccccctg aacctgaaac ataaaatgaa
4380tgcaattgtt gttgttaact tgtttattgc agcttataat ggttacaaat
aaagcaatag 4440catcacaaat ttcacaaata aagcaatagc atcacaaatt
tcacaaataa agcatttttt 4500tcactgcatt ctagttgtgg tttgtccaaa
ctcatcaatg tatcttatca tgtcgagcta 4560gctgtacaat cgatagatct
aggcctcctt cgccggccgc tcagcgaggg ggcagggcct 4620gcatgtgaag
ggcgtcgtag gtgtccttgg tggctgtact gagaccctgg taaaggccat
4680cgtgcccctt gcccctccgg cgctcgcctt tcatcccaat ctcactgtag
gcctccgcca 4740tcttatcttt ctgcagttca ttgtacaggc cttcctgagg
gttcttcctt ctcggctttc 4800cccccatctc agggtcccgg ccacgtctct
tgtccaaaac atcgtactcc tctcttcgtc 4860ctagattgag ctcgttatag
agctggttct ggccctgctg gtacgcgggg gcgtctgcgc 4920tcctgctgaa
cttcactctg aagaagatgc
ctagcccaat gaaaagcagg aggccggcga 4980cgccccccag cacaatcagg
gccattttac ctagggacag ggagaggctc ttctgtgtgt 5040agtggttgtg
cagagcctca tgcatcacgg agcatgagaa gacattcccc tcctgccacc
5100tgctcttgtc cacggttagc ctgctgtaga ggaagaagga gccgtcggag
tccagcacgg 5160gaggcgtggt cttgtagttg ttctccggct gcccattgct
ctcccactcc acggcgatgt 5220cgctggggta gaagcctttg accaggcagg
tcaggctgac ctggttcttg gtcatctcct 5280cctgggatgg gggcagggtg
tacacctgtg gctctcgggg ctgccctttg gctttggaga 5340tggttttctc
gatggaggac gggaggcctt tgttggagac cttgcacttg tactccttgc
5400cgttcagcca gtcctggtgc aggacggtga ggacgctgac cacacggtac
gtgctgttga 5460actgctcctc ccgcggcttt gtcttggcat tatgcacctc
cacgccatcc acgtaccagt 5520tgaactggac ctcggggtct tcctggctca
cgtccaccac cacgcacgtg acctcagggg 5580tccgggagat catgagagtg
tccttgggtt ttggggggaa caggaagact gatggtcccc 5640ccaggaactc
aggtgctggg catggtgggc atgggggacc atatttggac tcgttgaacc
5700gtccctcgcg aaaaagtttc tttaaatgta agagcaggtc ctttacaaac
tgggccacct 5760cgattttggt gtctcggaca tgcaagctgg aaaactgccc
agctgagacc ttgtgcgggc 5820agaatccgct cagcatcctc tgggtcttct
cgatggcact gcagcctgac acgttgatca 5880gggattccag ggctgcacag
tacatgccag ctgtcaggtt gatgctccat accatgctgc 5940cattgcagag
cggagccttc tggttctggg tgatgttgac cagctcctca atgaggtacc
6000tgagggctgt agagggaggc acagggcctg ggatcaggag gaatgctggg
tgtggtaact 6060cacagagcag aaggcttgtc accaggagaa gcatggtggc
ggctctaggg tgatctcagc 6120tgtaggaaag agaagaaggt tagtagtcga
cgtgtccctc tcgatgaatc cgtatcaatt 6180gtgagcgctc acaagtcaac
actctttttg ataaatctag tagatatcac ttacgtaggc 6240gccggtcaca
gcttggatct gtaacggcgc agaacagaaa acgaaacaaa gacgtagagt
6300tgagcaagca gggtcaggca aagcgtggag agccggctga gtctaggtag
gctccaaggg 6360agcgccggac aaaggcccgg tctcgacctg agctttaaac
ttacctagac ggcggacgca 6420gttcaggagg caccacaggc gggaggcggc
agaacgcgac tcaaccggcg tggatggcgg 6480cctcaggtag ggcggcgggc
gcgtgaagga gagatgcgag cccctcgaag cttcagctgt 6540gttctggcgg
caaacccgtt gcgaaaaaga acgttcacgg cgactactgc acttatatac
6600ggttctcccc caccctcggg aaaaaggcgg agccagtaca cgacatcact
ttcccagttt 6660accccgcgcc accttctcta ggcaccggtt caattgccga
cccctccccc caacttctcg 6720gggactgtgg gcgatgtgcg ctctgcccac
tgacgggcac cggagcgatc gcagatcctt 6780cga 678317497PRTHomo sapiens
17Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro1
5 10 15Ala Phe Leu Leu Ile Pro Gly Pro Val Pro Pro Ser Thr Ala Leu
Arg 20 25 30Tyr Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys
Ala Pro 35 40 45Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr
Ala Gly Met 50 55 60Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser
Gly Cys Ser Ala65 70 75 80Ile Glu Lys Thr Gln Arg Met Leu Ser Gly
Phe Cys Pro His Lys Val 85 90 95Ser Ala Gly Gln Phe Ser Ser Leu His
Val Arg Asp Thr Lys Ile Glu 100 105 110Val Ala Gln Phe Val Lys Asp
Leu Leu Leu His Leu Lys Lys Leu Phe 115 120 125Arg Glu Gly Arg Phe
Asn Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 130 135 140Cys Pro Ala
Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro145 150 155
160Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
165 170 175Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln
Phe Asn 180 185 190Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg 195 200 205Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val 210 215 220Leu His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser225 230 235 240Asn Lys Gly Leu Pro
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 245 250 255Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu 260 265 270Glu
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 275 280
285Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
290 295 300Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
Ser Phe305 310 315 320Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser
Arg Trp Gln Glu Gly 325 330 335Asn Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr 340 345 350Thr Gln Lys Ser Leu Ser Leu
Ser Leu Gly Lys Met Ala Leu Ile Val 355 360 365Leu Gly Gly Val Ala
Gly Leu Leu Leu Phe Ile Gly Leu Gly Ile Phe 370 375 380Phe Arg Val
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln385 390 395
400Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
405 410 415Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
Gly Gly 420 425 430Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
Asn Glu Leu Gln 435 440 445Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
Ile Gly Met Lys Gly Glu 450 455 460Arg Arg Arg Gly Lys Gly His Asp
Gly Leu Tyr Gln Gly Leu Ser Thr465 470 475 480Ala Thr Lys Asp Thr
Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro 485 490
495Arg18691PRTArtificial Sequenceselection/ suicide fusion coding
region containing herpes simplexvirus and E.coli sequences 18Met
Lys Lys Pro Glu Leu Thr Ala Thr Ser Val Ala Lys Phe Leu Ile1 5 10
15Glu Lys Phe Asp Ser Val Ser Asp Leu Met Gln Leu Ser Glu Gly Glu
20 25 30Glu Ser Arg Ala Phe Ser Phe Asp Val Gly Gly Arg Gly Tyr Val
Leu 35 40 45Arg Val Asn Ser Cys Ala Asp Gly Phe Tyr Lys Asp Arg Tyr
Val Tyr 50 55 60Arg His Phe Ala Ser Ala Ala Leu Pro Ile Pro Glu Val
Leu Asp Ile65 70 75 80Gly Glu Phe Ser Glu Ser Leu Thr Tyr Cys Ile
Ser Arg Arg Ala Gln 85 90 95Gly Val Thr Leu Gln Asp Leu Pro Glu Thr
Glu Leu Pro Ala Val Leu 100 105 110Gln Pro Val Ala Glu Leu Met Asp
Ala Ile Ala Ala Ala Asp Leu Ser 115 120 125Gln Thr Ser Gly Phe Gly
Pro Phe Gly Pro Gln Gly Ile Gly Gln Tyr 130 135 140Thr Thr Trp Arg
Asp Phe Ile Cys Ala Ile Ala Asp Pro His Val Tyr145 150 155 160His
Trp Gln Thr Val Met Asp Asp Thr Val Ser Ala Ser Val Ala Gln 165 170
175Ala Leu Asp Glu Leu Met Leu Trp Ala Glu Asp Cys Pro Glu Val Arg
180 185 190His Leu Val His Ala Asp Phe Gly Ser Asn Asn Val Leu Thr
Asp Asn 195 200 205Gly Arg Ile Thr Ala Val Ile Asp Trp Ser Glu Ala
Met Phe Gly Asp 210 215 220Ser Gln Tyr Glu Val Ala Asn Ile Phe Phe
Trp Arg Pro Trp Leu Ala225 230 235 240Cys Met Glu Gln Gln Thr Arg
Tyr Phe Glu Arg Arg His Pro Glu Leu 245 250 255Ala Gly Ser Pro Arg
Leu Arg Ala Tyr Met Leu Arg Ile Gly Leu Asp 260 265 270Gln Leu Tyr
Gln Ser Leu Val Asp Gly Asn Phe Asp Asp Ala Ala Trp 275 280 285Ala
Gln Gly Arg Cys Asp Ala Ile Val Arg Ser Gly Ala Gly Thr Val 290 295
300Gly Arg Thr Gln Ile Ala Arg Arg Ser Ala Ala Val Trp Thr Asp
Gly305 310 315 320Cys Val Glu Val Ala Ser Ala Phe Asp Gln Ala Ala
Arg Ser Arg Gly 325 330 335His Ser Asn Arg Arg Thr Ala Leu Arg Pro
Arg Arg Gln Gln Glu Ala 340 345 350Thr Glu Val Arg Pro Glu Gln Lys
Met Pro Thr Leu Leu Arg Val Tyr 355 360 365Ile Asp Gly Pro His Gly
Met Gly Lys Thr Thr Thr Thr Gln Leu Leu 370 375 380Val Ala Leu Gly
Ser Arg Asp Asp Ile Val Tyr Val Pro Glu Pro Met385 390 395 400Thr
Tyr Trp Arg Val Leu Gly Ala Ser Glu Thr Ile Ala Asn Ile Tyr 405 410
415Thr Thr Gln His Arg Leu Asp Gln Gly Glu Ile Ser Ala Gly Asp Ala
420 425 430Ala Val Val Met Thr Ser Ala Gln Ile Thr Met Gly Met Pro
Tyr Ala 435 440 445Val Thr Asp Ala Val Leu Ala Pro His Ile Gly Gly
Glu Ala Gly Ser 450 455 460Ser His Ala Pro Pro Pro Ala Leu Thr Leu
Ile Phe Asp Arg His Pro465 470 475 480Ile Ala Ala Leu Leu Cys Tyr
Pro Ala Ala Arg Tyr Leu Met Gly Ser 485 490 495Met Thr Pro Gln Ala
Val Leu Ala Phe Val Ala Leu Ile Pro Pro Thr 500 505 510Leu Pro Gly
Thr Asn Ile Val Leu Gly Ala Leu Pro Glu Asp Arg His 515 520 525Ile
Asp Arg Leu Ala Lys Arg Gln Arg Pro Gly Glu Arg Leu Asp Leu 530 535
540Ala Met Leu Ala Ala Ile Arg Arg Val Tyr Gly Leu Leu Ala Asn
Thr545 550 555 560Val Arg Tyr Leu Gln Cys Gly Gly Ser Trp Arg Glu
Asp Trp Gly Gln 565 570 575Leu Ser Gly Thr Ala Val Pro Pro Gln Gly
Ala Glu Pro Gln Ser Asn 580 585 590Ala Gly Pro Arg Pro His Ile Gly
Asp Thr Leu Phe Thr Leu Phe Arg 595 600 605Ala Pro Glu Leu Leu Ala
Pro Asn Gly Asp Leu Tyr Asn Val Phe Ala 610 615 620Trp Ala Leu Asp
Val Leu Ala Lys Arg Leu Arg Ser Met His Val Phe625 630 635 640Ile
Leu Asp Tyr Asp Gln Ser Pro Ala Gly Cys Arg Asp Ala Leu Leu 645 650
655Gln Leu Thr Ser Gly Met Val Gln Thr His Val Thr Thr Pro Gly Ser
660 665 670Ile Pro Thr Ile Cys Asp Leu Ala Arg Thr Phe Ala Arg Glu
Met Gly 675 680 685Glu Ala Asn 690
* * * * *